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ABSTRACT 
 
Kristin Zeneé Black: The Birth Outcomes and Reproductive Needs of Premenopausal Breast 
Cancer Survivors: A Mixed Methods Study 
(Under the direction of Diane L. Rowley) 
 
 
 This mixed methods dissertation examined the risk of adverse birth outcomes, and the 
reproductive and sexual health needs of premenopausal breast cancer survivors in North 
Carolina.  Using multivariable binomial regression, the first paper examined the prevalence of 
preterm birth (PTB) and low birthweight (LBW) according to breast cancer history prior to 
infant delivery and evaluated potential effect modification by race using statewide linked birth 
certificate files and Central Cancer Registry data from 1990-2009.  A breast cancer history 
corresponded to 50-67% increases in risk of delivering a PTB or LBW infant compared to the 
general population, with greater increases among women who received chemotherapy or gave 
birth within two years of diagnosis.  The higher prevalence of PTB and LBW associated with a 
breast cancer history was greater for white versus black mothers.  The second paper explored the 
reproductive healthcare needs of breast cancer survivors by exploring the concordances and 
discordances of their reproductive and sexual health needs by post-diagnosis childbearing status 
and race.  Seventeen North Carolinian women with a breast cancer history and diagnosed 
between the ages of 18-45 participated in a two-part, semi-structured interview.  We utilized 
ResearchTalk’s Sort and Sift, Think and Shift© Method, a multidimensional qualitative analysis 
approach.  This approach, along with member checking the findings with a community advisory 
committee and participants, allowed us to identify the most salient themes from the data.  The 
five overarching themes were that women with a breast cancer history: 1) received limited 
reproductive health information; 2) desired realistic expectations of conceiving post-cancer; 3) 
 iv 
made lifestyle choices based on family breast cancer history; 4) struggled with adjusting to their 
altered physical appearance; and 5) had menopause symptoms that led to sexual health and 
quality of life issues.  Despite the many concordances in experiences, there were subtle 
discordances by post-diagnosis childbearing status and race.  Women with a breast cancer 
history desire more education and resources to address their reproductive and sexual health 
concerns and would greatly benefit from receiving reproductive and sexual health counseling 
during breast cancer treatment and beyond. 
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CHAPTER 1: INTRODUCTION 
Although breast cancer is considered a disease of the aging population, in 2013, 21.74% 
(64,560 out of 296,980) of women diagnosed with breast cancer were under the age of 50.(1)  
Due to the advancement of screening and treatment options for breast cancer, more women are 
able to live fruitful lives after a breast cancer diagnosis (2), yet for premenopausal breast cancer 
survivors little is known about the effects of the disease and treatment on their reproductive 
capacity and birth outcomes.  With the co-occurrence of two trends, an increasing number of 
women delaying their first birth into their thirties and early forties (3,4) and the improvement of 
survival rates of women diagnosed with breast cancer before the age of 50 (5), there is a greater 
possibility that many young breast cancer patients have not yet started or completed their 
families at the time of diagnosis and may desire to have children after successful completion of 
their cancer treatment regimen. 
Even though white women tend to have a higher incidence of postmenopausal breast 
cancer than black women, there is a dynamic crossover between black and white women when 
looking at premenopausal breast cancer.(6)  In 2013, the age-adjusted incidence of breast cancer 
in women diagnosed under the age of 50 was 45.3 per 100,000, with black women under age 50 
having an incidence of 41.5 and white women under age 50 having an incidence of 45.6.  This 
black-white disparity is also evident in the 5-year relative survival rates.  The overall 5-year 
breast cancer survival rate for women under the age of 50 at diagnosis is 90.7%; however, it is 
81.7% for black and 92.0% for white women.(7)   
Breast cancer diagnosed in young women is more likely to present at an advanced stage, 
be more aggressive, and have a poorer prognosis than breast cancer diagnosed in older women 
(8); moreover, young black women (when compared to white women, especially older white 
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women) are more likely to be diagnosed with basal-like tumors (i.e., ER-negative, PR-negative, 
HER2-negative, and either HER2-positive or CK 5/6-positive) (9,10), often referred to as triple-
negative breast cancer (1,11), which is the most aggressive sub-type of breast cancer.  Although a 
triple-negative breast cancer diagnosis is relatively rare, women diagnosed with triple-negative 
breast cancer have a poorer short-term prognosis than women with other types of breast cancer 
since triple-negative tumors are less responsive to treatment.(1)  
In the general United States population, 9.6% of infants are delivered preterm (<37 
weeks gestation) and 8.1% have a low birthweight (<2,500 grams).  The preterm birth and low 
birthweight rates vary widely by race/ethnicity and maternal age.  In 2015, black women were 
40.5% more likely to deliver a preterm infant and 63.2% more likely to deliver a low birthweight 
infant compared to white women.(12)  Mothers under the age of 15 or mothers aged 45 or older 
have a higher rate of delivering an infant before 37 weeks of gestation or less than 2,500 grams 
than mothers aged 25-34 years.(4)   
There are clear black-white disparities in breast cancer incidence and 5-year survival 
rates, as well as birth outcomes since black women (when compared to white women) are more 
likely to be diagnosed with breast cancer before the age of 40 (1,6) and to deliver a preterm or 
low birthweight infant.(12)  Additionally, the current literature is inconsistent about the 
potential risk of adverse birth outcomes among breast cancer survivors.(13–21)  Considering the 
potential pregnancies that may occur among premenopausal breast cancer survivors, the 
specific aims of this study were to: 1) determine if premenopausal breast cancer survivors (ages 
18-45) in North Carolina who had a live birth after their diagnosis have a greater prevalence of 
delivering a preterm or low birthweight infant (PTB; LBW) than women in North Carolina who 
had a live birth and have never been diagnosed with breast cancer; and 2) determine the unmet 
reproductive and preconception healthcare needs of premenopausal breast cancer survivors. 
A mixed methods approach was used to explore the proposed aims.  For Aim 1, a case-
cohort study was conducted using a linked dataset of North Carolina cancer registry and birth 
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record data.  The dataset includes about 2.3 million births that occurred between 1990-2009, 
including 512 births to breast cancer survivors.  Aim 2 involved the collection of primary data by 
conducting two 45-60-minute in-depth, semi-structured interviews with 17 women with a 
history of breast cancer to learn about the reproductive health needs that may (or may not) have 
been met after their cancer diagnosis.  The findings from the quantitative and qualitative 
methods were integrated to develop a more complete story about the reproductive health 
experiences of premenopausal breast cancer survivors. 
 
Significance 
Few published studies have examined the potential association between cancer and 
subsequent birth outcomes (16–18); a few notable studies have specifically focused on breast 
cancer and birth outcomes.(13–15,19–21)  Yet, a majority of the studies of premenopausal breast 
cancer survivors have focused on pregnancy and survival rates after a pregnancy.(13–15,19,22)  
These types of studies do not provide a comprehensive perspective of the reproductive health 
experiences and challenges that premenopausal breast cancer survivors face.  In order to 
understand the complexities surrounding the reproductive health issues of premenopausal 
breast cancer survivors, it is important to know about the biology of breast cancer in younger 
women, the effect of chemotherapy on reproductive health, the reproductive health concerns of 
young breast cancer survivors, risk predictors and factors for preterm birth and low birthweight, 
and the importance of preconception healthcare. 
 
Studies on Breast Cancer and Birth Outcomes 
Out of six studies that have focused on the birth outcomes of premenopausal breast 
cancer survivors, three are population-based studies (19–21), two are cross-sectional 
retrospective survey studies (14,15), and one is a single-center case report.(13)  There are four 
main limitations that are apparent throughout these six studies: 1) the inability to determine 
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which women are fertile and desire to have children (or not) (15,19–21); 2) the lack of maternal 
characteristics controlled for in the statistical analysis models (15,19,21); 3) the use of self-
reported birth outcomes via survey instruments (14,15); and 4) relatively small study 
populations.(13,19)  An additional issue to consider when focusing on the premenopausal breast 
cancer survivor population is the desire of these women to pursue motherhood and the potential 
selection bias introduced by the “healthy mother effect” that may be occurring since the 
“healthier” breast cancer survivors may be more fit and willing to become pregnant post-
diagnosis and treatment.(19,23,24)   
Three seminal, population-based studies that examined the birth outcomes of women 
diagnosed with breast cancer have been conducted in Denmark, Sweden, and western Australia 
(19–21) and these particular studies will serve as a model for the proposed study.  These studies 
use linked cancer and birth registry data from nationwide healthcare data systems that have 
been active as early as the 1940s and collect data on every resident from birth to death.  Despite 
having access to nearly complete, population-based data, these studies did not have consistent 
results on the potential risk of breast cancer survivors delivering preterm and low birthweight 
infants.   
Langagergaard et al. (21) studied 216 births to breast cancer survivors with a median of 
753 days (Range: 3-5965 days) from time of diagnosis until pregnancy (i.e., 1st day in last 
menstruation) and found no substantial increase in odds of low birthweight (aPOR: 1.3; 95% CI: 
0.7-2.2) or odds of preterm birth (aPOR: 1.2; 95% CI: 0.4-3.8).  When the analysis was stratified 
by type of breast cancer treatment, the overall results did not change.  Infants born to breast 
cancer survivors had nearly the same mean birthweights as infants born to the comparison 
group of mothers who were not diagnosed with breast cancer.  
The results of the Dalberg (20) study of 331 births to nulliparous women with a history of 
invasive breast cancer over a similar time period reached results that conflicted with the 
Langagergaard study.  Dalberg et al. found that 11% of the infants born to women exposed to 
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breast cancer were delivered preterm compared with 5% of infants born to women not exposed 
to breast cancer.  The odds of delivering an infant at less than 32 weeks of completed gestation 
for breast cancer survivors was 3.20 (95% CI: 1.70-6.03) times the odds for a woman not 
exposed to breast cancer.  These odds were slightly lower when the infants were born between 
32 and 36 weeks gestation (aOR: 1.53; 95% CI: 1.02-2.29).  The odds of delivering an infant that 
weighed less than 1,500 grams for breast cancer survivors was 2.86 (95% CI: 1.41-5.78) times 
the odds for a woman not exposed to breast cancer.  
The Ives (19) study used one of the most extensive population-based databases to 
examine fertility and birth outcomes among breast cancer survivors, since the public and private 
health records they used included data from the hospital morbidity database, birth and death 
registries, mental health services, cancer registry, and midwives’ notifications.  Out of the 2,539 
breast cancer survivors between the ages of 15 and 44 in the study, 5% (n=123) had at least one 
pregnancy after diagnosis.  These cases were compared to a control group that consisted of 
western Australian women who had at least one pregnancy between 1983-2004.  Ives et al. 
found that the pregnancy rate was lower among the breast cancer survivors and they tended to 
be older than the general population.  Fifty percent of the breast cancer survivors (n=62) had a 
birth within two years of their diagnosis date and there were only two preterm births reported. 
This stark difference in the findings from these three population-based studies suggest 
that these past studies have not provided us with the full picture of the effects of breast cancer 
on subsequent birth outcomes.  Therefore, there are still additional avenues that need to be 
explored in order to learn more about the birth outcomes among this specific population. 
The persistent limitations in the current literature are mostly related to study design.  
The complexity of this topic signifies a need to conduct studies that employ quantitative and 
qualitative approaches, which includes using stronger epidemiological study methods with 
population-based samples, examining risk predictors and risk factors (e.g., maternal 
characteristics), and incorporating the personal insights of breast cancer survivors.  The 
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National Institutes of Health (NIH) working group on developing best practices for mixed 
methods research recommends that mixed methods approaches are appropriately used in 
studies that aim to acquire a real life understanding of contextual or cultural influences on an 
identified outcome (25), which the proposed study aimed to achieve.   
 
The Biology of Breast Cancer in Young Women 
Breast cancer diagnosed in young women tends to present at an advanced stage, is more 
aggressive, and has a poorer prognosis than breast cancer diagnosed in older women.(8)  
Premenopausal breast cancer patients have poorer prognoses compared to older breast cancer 
patients, which may be due to the differences in biology of breast cancer in young 
women.(26,27)  Factors that determine a patient’s breast cancer prognosis, include tumor size, 
histologic tumor grade, nodal status, metastatic stage, immunohistochemical markers (e.g., 
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 
(HER1, HER2), and cytokeratin (CK) 5/6 status), likelihood of recurrence, menopausal status, 
and age, among other things.  Premenopausal women are more likely to be diagnosed with 
invasive breast cancers, such as infiltrating ductal carcinomas, to present with larger tumors 
(28,29), and have higher grade, ER-negative tumors.(30)  One study found that when compared 
to premenopausal breast cancer patients aged ≥35 years, women aged <35 years were more 
likely to have tumors classified as ER-negative (38.8 versus 21.6%, p-value<0.001) and PR-
negative (49.1 versus 35.3%, p-value<0.001).(30)  About 60% of premenopausal breast cancer 
patients have ER-positive tumors, which are the tumors that are the most responsive to 
hormonal therapy.(31)  However, when compared to older women, young women, especially 
young black women (9,32–34), are more likely to be diagnosed with basal-like tumors (i.e., ER-
negative, PR-negative, HER2-negative, and either HER2-positive or CK 5/6-positive) (9,35), 
often referred to as triple-negative breast cancer (1,11), which is one of the most aggressive sub-
types of breast cancer for all women, regardless of race/ethnicity.(10)  Women diagnosed with 
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triple-negative breast cancer have a poorer short-term prognosis than women with other types 
of breast cancer since triple-negative tumors are less responsive to treatment (1), more likely to 
relapse within the first five years after diagnosis (36), and associated with higher mortality 
compared to the most common sub-type, luminal A (i.e., ER-positive or PR-positive and HER2-
negative).(10)  The classification of breast cancer sub-types is evolving, as indicated by O’Brien 
et al.’s (10) research and the current literature is not consistent on the use of basal-like versus 
triple-negative when classifying this specific sub-type of breast cancer.  This is a particularly 
important issue to consider because premenopausal breast cancer patients are diagnosed with 
basal-like breast cancer at higher rates (31) and the O’Brien study (10) reported differences in 
the hazard ratios of breast cancer-related death when the usually all-inclusive triple-negative 
sub-type is teased apart into three sub-types (e.g., basal-like, HER-positive/ER-negative, 
unclassified).  When breast cancer sub-types information is available, it should be well defined 
based on the current literature. 
 
Effect of Cancer Treatment on Reproductive Health 
Adjuvant endocrine therapy, which is the treatment of breast cancer with hormonal 
manipulation and/or cytotoxic therapies, is recommended for premenopausal breast cancer 
patients, because it improves the likelihood of relapse-free and overall survival by treating 
undetectable micrometastases.(31,37)  Premenopausal breast cancer patients with hormone 
receptor-positive tumors are encouraged to receive adjuvant endocrine therapy that includes 
chemotherapy treatment and hormonal treatment (e.g., tamoxifen) for up to five years since it 
can reduce the 15-year death rate from breast cancer by 57% for women younger than 50 years 
old at time of diagnosis.(5)  Tamoxifen does not improve recurrence or death rates for women 
with hormone receptor-negative disease; chemotherapy is beneficial for this group.(38) 
Even though many of the side effects of chemotherapy are reversible once treatment is 
completed, the effects of this treatment on the ovaries can be irreversible.(39)  Chemotherapy 
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has been shown to cause damage to female cancer patients’ reproductive functioning by 
destroying mature ovarian follicles and causing ovarian toxicity.  The resulting damage from 
chemotherapy treatment can range from temporary amenorrhea where menses returns post-
treatment to complete ovarian failure or the early onset of menopause.  Although it is highly 
likely that most women will experience menstrual cycle irregularity during chemotherapy 
treatment, it is expected that menstruation will return for premenopausal women within six 
months after the completion of the treatment.  The type of chemotherapeutic agent, cumulative 
dose of the drug, duration of the treatment, age of the cancer patient, and pre-treatment ovarian 
reserve are all factors that determine a female cancer patient’s likelihood of developing post-
chemotherapy ovarian failure.(31,37,39,40)  A longitudinal observational study assessing 
menstrual cycle maintenance and quality of life after breast cancer determined that after the 
completion of chemotherapy treatment, premenopausal breast cancer survivors under the age of 
35 had an 85% recovery rate of their monthly menses.  Breast cancer survivors ages 35 to 40 had 
a 45-61% recovery rate and those older than age 40 were the least likely to regain their 
menstrual cycle after the completion of treatment and during the study’s follow-up period.(41)  
Yet, permanent amenorrhea may be desirable for some breast cancer patients since it is 
associated with increased survival.  In a retrospective observational study of premenopausal 
breast cancer patients in Seoul, Korea, it was determined that 5-year disease-free survival was 
slightly higher for women who experienced chemotherapy-induced amenorrhea (88.0%) 
compared to women who did not (85%).(42) 
It is recommended that breast cancer survivors, particularly those with hormone 
receptor-positive tumors, use non-hormonal birth control methods to decrease their risk of 
recurrence.  They are also often asked to refrain from becoming pregnant while using tamoxifen, 
because it may have teratogenic effects on a fetus.(39)  Premenopausal breast cancer patients 
with ER-positive tumors are highly encouraged to use tamoxifen for at least five years after the 
completion of chemotherapy and/or radiation treatment, since the use of this adjuvant 
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endocrine (hormonal) therapy decreases the risk of recurrence.  The risk of becoming 
menopausal while taking tamoxifen increases with age.  For tamoxifen users, less than 5% of 
women under age 40 become menopausal.  This increases to 30% of women over age 40 and 
becomes as high as 84% of women who received chemotherapy and hormonal therapy.(43) 
Although most studies conclude that in general breast cancer treatment is not associated 
with adverse birth outcomes (13–19,21), the Dalberg et. al (20) study did find that breast cancer 
survivors who have received chemotherapy treatment and have a subsequent pregnancy do have 
an increased risk of delivering a preterm or low birthweight infant. 
It is highly recommended that cancer care providers discuss fertility preserving options 
with their premenopausal breast cancer patients before beginning treatment, so that they are 
fully aware of the effect each treatment may have on their reproductive function.(39,40)  This 
information is particularly important to discuss with women who have not started or completed 
their families, so they can make an informed decision about the most appropriate cancer 
treatment regimen for them and if there are any fertility preserving options they should pursue 
prior to the onset of treatment.  The most popular and effective fertility preservation options 
are: 1) Pharmacologic treatment (e.g., gonadotropin releasing-hormone agonist (GnRHa) for 
ovarian protection, apoptotic inhibitors); 2) Ovarian transposition (oophorophexy); and 3) 
Assisted reproductive technologies (e.g., cryopreservation of embryos, cryopreservation of 
oocytes, ovarian tissue cryopreservation, artificial gametes).(31,39,40)  According to Resolve, 
the National Infertility Association, the average cost of assisted reproductive technologies (ART) 
ranges from $865 to $8165 per cycle or procedure.(44)  However, insurance companies usually 
do not cover fertility preservation or infertility treatments (39), which make these options 
unfeasible for many breast cancer patients who cannot afford the out-of-pocket expense for 
these treatments. 
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This body of knowledge suggests that breast cancer treatments may impact one’s 
reproductive capacity, and therefore serve as a mediator in the relationship between breast 
cancer diagnosis and adverse birth outcomes.   
 
Reproductive Health Concerns among Premenopausal Breast Cancer Survivors 
The long-term reproductive impact of cancer treatments is a legitimate concern for 
premenopausal breast cancer survivors.  There are three main reasons that a diagnosis of 
premenopausal breast cancer may negatively impact reproductive function: 1) the toxic effect of 
chemotherapy on ovarian follicles (31,37,39,40), as discussed above; 2) the common 
recommendation for breast cancer patients to delay pregnancy for at least two to three years 
post-diagnosis (31,39); and 3) the recommendation to not become pregnant during adjuvant 
endocrine therapy, which lasts for five (but up to ten) years post-diagnosis, which may 
contribute to an age-related decline in fertility.(31)   
The two to three year time delay between a breast cancer diagnosis and becoming 
pregnant is recommended because there is a concern of the lingering toxic effects of treatment 
on growing oocytes and there is also the potential risk of recurrence during this period.(39)  
However, evidence exhibiting the benefit to patients of waiting more than two years post-
diagnosis to become pregnant is limited, especially if the woman has a good prognosis and 
localized disease (19), adjuvant endocrine therapy has been completed (31), and the risk of 
recurrence is low.(39,45,46)  Young women diagnosed with breast cancer often question if a 
pregnancy will increase their risk of breast cancer recurrence because breast cancer is hormone-
dependent and pregnancy is a period when hormone levels are at an all-time high in a women’s 
reproductive life-span.  The main concern is that an increase in hormone levels during 
pregnancy may stimulate the growth of remaining breast cancer cells or dormant 
micrometastasis, which may in turn increase the risk of recurrence.(39)  Yet, breast cancer 
survivors who become pregnant after the completion of treatment tend to have the same, if not 
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better survival rates (22,46,47) and are less likely to experience a recurrence of breast cancer 
(48) than women who do not become pregnant after a breast cancer diagnosis.  In a study by 
Gelber and colleagues (22), the overall 5-year and 10-year survival rates for breast cancer 
survivors who became pregnant was 92% and 85%, while 5-year survival was 85% and 10-year 
survival was 74% for the matched non-pregnant breast cancer survivor control group.  The 
results from this study support the healthy mother effect (19,23,24), which is a type of selection 
bias that may indicate that women who choose to and are able to become pregnant after a bout 
with breast cancer may be healthier in general compared to breast cancer survivors who choose 
not to or are not able to become pregnant.(24,31) 
Since it is recommended that women take tamoxifen for a minimum of five years and up 
to ten years, this extends the period breast cancer survivors must wait to become pregnant, if 
they desire.  Within this five- to ten- year waiting period, these women, particularly the older 
premenopausal breast cancer survivors, may become menopausal or suffer from infertility due 
to diminished oocyte reserves.(37,39)  
The potential damaging effects of chemotherapy and hormonal therapy on reproductive 
function, as well as the age-related decline in fertility from delaying childbearing until the 
completion of treatment are all reproductive health issues that premenopausal breast cancer 
patients need to be informed of before, during, and after the completion of treatment so they are 
fully aware of the impact the cancer treatments may have on their plans to begin or complete 
their families.  More information is needed to determine if these cancer treatments may have 
any influence on the birth outcomes of infants born to premenopausal breast cancer survivors. 
 
Risk Predictors and Factors of Preterm Birth and Low Birthweight 
The risk of delivering a preterm or low birthweight infant is known to vary by several 
maternal characteristics, including mother’s age at time of pregnancy, race/ethnicity, and 
socioeconomic status.(49–51)  Furthermore, studies that have focused on disparities in medical 
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treatment and health outcomes have demonstrated that racial/ethnic and socioeconomic status 
(SES) disparities are particularly apparent among cancer patients.(17,18,52–54)  Therefore, 
maternal characteristics, race/ethnicity, and SES were important variables to include in this 
study’s analytical models in order to determine if they are true effect measure modifiers or 
confounders in the association between premenopausal breast cancer and preterm birth or low 
birthweight.  Many past studies that have focused on the association between breast cancer and 
birth outcomes may have not seen a strong correlation between these variables because they did 
not factor in relevant risk predictors and factors that may influence this relationship. 
 
Preconception Health 
Preconception health interventions aim to improve the health status and behaviors of 
women (and men) prior to conceiving a child with the ultimate goal of decreasing the risk of 
adverse pregnancy-related outcomes.(55)  The preconception period in the life course often 
refers to the years in which one is of reproductive age, but also recognizes that a woman’s 
preconception health status may be the result of negative exposures in utero or her mother’s (or 
even maternal grandmother’s) lifestyle behaviors or exposures.  Since a majority of pregnancies 
are unplanned, there has been a growing emphasis on promoting healthy behaviors throughout 
the reproductive health period (e.g., smoking cessation, reduction in alcohol use, maintaining a 
healthy weight, consumption of essential vitamins and minerals) and not just during the 
prenatal period.(56) 
In 2007, the Centers for Disease Control and Prevention (CDC) established a working 
group to develop a set of core state preconception health indicators, which were included in five 
population-based data systems, including the Pregnancy Risk Assessment and Monitoring 
Survey (PRAMS) and the Behavioral Risk Factor Surveillance System (BRFSS).  The aim was to 
learn more about the preconception health status and behaviors of women in the U.S.  These 
indicators were organized into eleven domains, which are: 1) general health status and life 
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satisfaction; 2) social determinants of health; 3) healthcare; 4) reproductive health and family 
planning; 5) tobacco, alcohol, and substance use; 6) nutrition and physical activity; 7) mental 
health; 8) emotional and social support; 9) chronic conditions; 10) infections; and 11) 
genetics/epigenetics.(57)   
North Carolina is one of the original seven states that participated in the working group 
that developed these core indicators.  Medical, state health department, and university-based 
entities in North Carolina have been dedicated to improving the preconception health of women 
and men in this state.  In 2008, the North Carolina Preconception Health Coalition released a 
2009-2013 strategic plan to promote intended pregnancy and healthy weight.  The coalition’s 
other priority areas are substance abuse, mental health, collaborative research on 
preconception-focused topics, and policy development and access to care.(58)  This coalition is 
one example of how North Carolina is committed to educating women, men, and healthcare 
professionals about the importance of preconception health and is making strides towards 
providing more women in this state with access to preconception health services. 
When applied to special populations, such as women diagnosed with and treated for 
premenopausal breast cancer, the preconception healthcare needs may differ from those 
prescribed to the general population of women of reproductive age.  Therefore, it is important to 
learn more about the preconception health status and behaviors of special populations, so that 
the preconception health services referred to these women can be tailored to suit their specific 
reproductive health concerns that may be magnified by their health condition. 
 
Conceptual Foundation 
This study of the birth outcomes and reproductive needs of premenopausal breast cancer 
survivors provides additional insights into the lives and health of women after being treated for 
breast cancer.  Improvements in treatment options and early detection have led to more 
survivors living for longer periods of time after breast cancer.(59)  As breast cancer survivors 
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continue on with their lives, the medical and public health communities need to be prepared to 
address the health issues that may differ between breast cancer survivors and the general 
population.  
In an effort to address gaps in the literature, the proposed study explored the association 
between a premenopausal breast cancer diagnosis and delivering a PTB or LBW infant, as well 
as the reproductive needs and concerns of young breast cancer survivors.  Healthy mother effect 
bias (19,23,24), Lu’s and Halfon’s (60) life-course health development model, as well the 
biological effect of chemotherapy on reproductive function, served as the conceptual 
foundations for testing hypotheses regarding the effect of a breast cancer diagnosis on 
subsequent birth outcomes, as well as how this relationship is influenced by maternal 
characteristics and the length of time between breast cancer diagnosis and the date of first infant 
delivery post-breast cancer diagnosis.  This study utilized quantitative and qualitative methods 
with the aim of providing a comprehensive synopsis of the reproductive health experiences of 
premenopausal breast cancer survivors.  This information may assist medical and public health 
professionals with offering targeted preconception health services to this specific population in 
order to decrease their risk of experiencing an adverse birth outcome, as well as fully address 
their reproductive health concerns.  A directed acyclic graph (DAG) that visually depicts the 
relationship between breast cancer and PTB/LBW from an epidemiological perspective is 
provided in Figure 1.1. 
Not all of the pathways in the DAG were examined.  The main causal pathway from 
breast cancer diagnosis to PTB/LBW was the foundation of the analysis with maternal age at 
infant delivery, education, marital status, parity, and smoking being controlled for as 
confounders, race/ethnicity being accounted for as a modifier, and chemotherapy accounted for 
as a mediator.  In this study, chemotherapy was the main cancer treatment included in the 
analyses, due to its known negative effect on breast cancer patients’ reproductive health and 
birth outcomes.  Although fertility status (i.e., being premenopausal, peri-menopausal, or 
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menopausal after receiving cancer treatment) and body mass index are recognized in the DAG 
as important covariates on the pathway between the exposure and outcome, these variables are 
not available in the given dataset and therefore were not included in the analyses. 
To further exemplify the joint quantitative and qualitative analysis used in this study, the 
conceptual model in Figure 1.2 provides a more simplified depiction of the relationship between 
the aforementioned variables.  The conceptual model is adapted from Lu’s and Halfon’s (60) 
life-course health development model to reflect the trajectories of premenopausal breast 
survivors from diagnosis to a subsequent pregnancy.  The life-course health development model 
depicts how black and white women are differentially exposed to risk factors and protective 
factors over the life course and how this contributes to disparities in health outcomes.(60)  The 
life-course health development model exhibits how black women have more cumulative 
exposure to risk factors (i.e., downward arrows) and less protective factors (i.e., upward arrows) 
than their white counterparts, which results in black women having lower reproductive potential 
over their life course.  The conceptual model depicts how this situation may look for 
premenopausal breast cancer survivors.   
There are a few key points represented in this conceptual model.  The period in which 
women are undergoing chemotherapy is when both black and white women’s reproductive 
potential exponentially declines, but this decline is more dramatic for black women than white 
women based on the hypothesis that black women have a greater cumulative exposure to risk 
versus protective factors compared to white women.  Furthermore, the hormonal therapy-
related and age-related decline in reproductive potential declines more slowly for white than 
black women based on the hypothesis that white women experience more protective versus risk 
factors compared to black women.  It is also important to note that due to the healthy mother 
effect, the women who are able to become pregnant after a premenopausal breast cancer 
diagnosis are more likely to have a more positive prognosis and be represented in this model.  
The quantitative dataset allowed for an examination of how risk factors and protective factors 
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(e.g., maternal characteristics) differentially influence the birth outcomes of black and white 
women with and without a breast cancer history.  Whereas, the qualitative dataset allowed for 
the further exploration of the reproductive potential of premenopausal breast cancer survivors 
by also including women who did not have children, either by choice or due to infertility issues. 
 
Study Overview 
A mixed methods approach provides an avenue to explore the complex relationship 
between breast cancer and reproductive health through the lived experiences of premenopausal 
breast cancer survivors.  In this study, the quantitative data provides an estimate of the 
prevalence ratios and confidence intervals of the association between a breast cancer history and 
preterm birth and low birthweight using linked cancer registry and birth record data from the 
North Carolina State Center for Health Statistics.  The qualitative data provides an 
understanding of the reproductive health experiences and concerns of women with a breast 
history, in addition to similarities and differences in experiences by post-diagnosis birth status 
and race using in-depth interviews with premenopausal breast cancer survivors.  The combined 
use of these methods sheds new light on this topic and provides a rich and more complex 
understanding of the reproductive health experiences of premenopausal breast cancer survivors. 
As strategies for screening and treatment continue to advance, survival rates for breast 
cancer will simultaneously increase; therefore, the preconception health issues that arise for 
premenopausal breast cancer survivors need to be sufficiently addressed.  Informed by the 
healthy mother effect bias theory (19,23,24), Lu’s and Halfon’s (60) life-course health 
development model, as well the biological effect of chemotherapy on reproductive function, this 
study adds to existing research by exploring additional factors that may influence the 
association between premenopausal breast cancer and subsequent birth outcomes for women in 
the United States.  This study adds a layer to this pertinent discussion by highlighting the risk 
predictors and factors that may contribute to this complex issue, including maternal 
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characteristics and chemotherapy treatment.  Furthermore, this study provides insights into the 
specific preconception health services and reproductive health counseling that women with a 
breast cancer history may benefit from prior to and after cancer treatment. 
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FIGURES 
Figure 1.1. Directed Acyclic Graph (DAG) of the relationship between breast cancer diagnosis 
and preterm birth or low birthweight accounting for potential covariates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY: 
*Green circle with play symbol is the exposure variable 
†Blue circle with bold I is the outcome variable 
♭Blue circles are the ancestors of the outcome variable 
‡Red circles are covariates that are potentially associated with the exposure and outcome (i.e., confounders) 
§Green line is the causal path 
#Red lines are the bias paths 
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Figure 1.2. Conceptual model of how risk factors and protective factors differentially influence 
the relative reproductive potential of black and white women with a premenopausal 
breast cancer history 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This model is adapted from Lu’s and Halfon’s life-course health development model (60) 
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CHAPTER 2: PREVALENCE OF PRETERM AND LOW BIRTHWEIGHT DELIVERY 
AFTER BREAST CANCER DIAGNOSIS: A POPULATION-BASED STUDY 
 
Introduction 
With an increasing number of women delaying childbearing (1,2) and improved breast 
cancer survival among women diagnosed before the age of 50 (3), many young breast cancer 
patients face decisions at the time of diagnosis that may influence their future reproductive 
health.  Beyond the risk of infertility (4–7), other adverse birth outcomes including preterm 
birth and low birthweight may be more common among women with a prior breast history.(8)  
The potential risk of adverse birth outcomes among breast cancer survivors has not been studied 
in in the context of existing racial disparities in breast cancer incidence and birth outcomes in 
the United States.   
Black women are more likely than their white counterparts to be diagnosed with breast 
cancer during their reproductive years (9) and deliver preterm or low birthweight infants.  
Breast cancer diagnosed in young women, especially young black women, is more likely to be 
more aggressive and have a poorer prognosis than breast cancer diagnosed in older women and 
young white women.(10–12)  In the general U.S. population, 9.6% of infants are delivered 
preterm (PTB; <37 weeks gestation) and 8.1% have a low birthweight (LBW; <2,500 grams).(2)  
Rates of PTB and LBW increases with maternal age and vary by race/ethnicity.  For example, 
mothers aged 45 or older compared to those aged 25-34 years have a higher portion of PTB 
(24.2 vs. 9.1%) and LBW (20.4 vs. 7.4%) deliveries.(13)  At the same time, black women are 
40.5% more likely to deliver a PTB infant and 63.2% more likely to deliver a LBW infant 
compared to white women.(2)  
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A breast cancer diagnosis and its treatment may have long-lasting effects on 
reproductive health outcomes.  Alkylating agent-based chemotherapies can cause ovarian 
toxicity (5), including loss of mature ovarian follicles.  During chemotherapy treatment, 
premenopausal women may experience temporary chemotherapy-related amenorrhea or 
premature ovarian failure.(4–7)  After completion of chemotherapy, a 5- to 10-year course of 
adjuvant endocrine therapy is recommended for hormonally-responsive tumors to improve 
relapse-free and overall survival.(6,7,14)  Pregnancy is not recommended during the course of 
adjuvant endocrine therapy; therefore, some women may choose to not initiate or to interrupt 
endocrine therapy to achieve pregnancy.(15) 
Black-white disparities in breast cancer incidence rates and birth outcomes raise 
concerns about potential disparities in the reproductive health of premenopausal breast cancer 
survivors.  Most previous studies have focused on survival rates among breast cancer survivors 
with a post-diagnosis pregnancy compared to those without.(16–18)  Survival does not appear to 
be adversely affected by post-diagnosis pregnancy; however, this may be partially attributable to 
a “healthy mother effect.”(16,19,20)  Few published studies have examined infant outcomes after 
a breast cancer diagnosis.(8,16,18,21–23)  Our study examined the prevalence of PTB and LBW 
according to breast cancer history prior to infant delivery in a population-based study in North 
Carolina (NC) and evaluated potential effect modification by race.   
 
Methods 
  This study was reviewed and approved by the University of North Carolina at Chapel 
Hill’s IRB and Office of Human Research Ethics (#14-1394).   
 
North Carolina Central Cancer Registry   
  The primary exposure for this analysis was breast cancer history prior to delivery.  We 
identified breast cancer diagnoses during the study period (1990-2009) within the state-
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mandated North Carolina Central Cancer Registry (NC-CCR).(24)  The NC-CCR is a gold-
certified North American Association of Central Cancer Registries (NAACCR) cancer registry 
within the Centers for Disease Control and Prevention’s National Program of Cancer Registries.  
We used topography site code C50 from the International Classification of Disease-Oncology, 3rd 
Edition (25) to identify first primary breast cancer diagnoses at ages 18-45.  Additional NC-CCR 
variables included date of diagnosis, age at diagnosis, and receipt of treatment (e.g., surgery, 
chemotherapy, radiation, endocrine therapy).  
 
North Carolina Birth Certificate Files  
   The study population for this analysis was comprised of all live, singleton births to NC 
residents during 1990-2009 (n=2,325,229).  Within ten days of a delivery, a hospital 
administrator or person attending a non-hospital delivery (e.g., midwife) must file a birth 
certificate to the Department of Health and Human Services.  The NC State Center for Health 
Statistics houses and manages these vital statistics records.(26)  Further eligibility criteria 
included maternal ages 18-50 years (n=2,213,487), and maternal ethnicity and race designated 
as non-Hispanic Black or White (n=1,916,998).  Latinas and other races/ethnicities were 
excluded because there was not sufficient power to examine these racial/ethnic categories 
independently. Women who experienced a stillbirth, miscarriage, or other adverse pregnancy 
outcome that did not result in a live birth are not included because they are not systematically 
captured in vital records data.  We also excluded mothers who delivered infants at less than 20 
weeks gestation or weighing less than 500 grams because they were outside of the age and 
weight of viability.  After these exclusions, 1,912,269 births contributed to the LBW analysis and 
1,910,014 births contribute to the PTB analysis (2,255 births were missing gestational age). 
   Information abstracted from the birth certificate files included number of weeks of 
gestation at time of delivery, infant’s weight in pounds and ounces, maternal number of years of 
education, marital status at time of delivery, number of living children, race, ethnicity, number 
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of cigarettes smoked per day during pregnancy, maternal age at delivery, and date of infant 
delivery. 
 
North Carolina Central Cancer Registry and Vital Records Linkage   
Birth certificate files were linked with the NC-CCR for the period of January 1, 1990 
through December 31, 2009, by the NC State Center for Health Statistics.  The linkage protocol 
applied a probabilistic algorithm using names and social security numbers in Link Plus (CDC; 
Atlanta, GA).  Identifying information was redacted from the final dataset.  Breast cancer history 
prior to infant delivery was defined as a maternal breast cancer diagnosis recorded in the NC-
CCR that preceded the date of delivery in the birth certificate files.  Two births by mothers with a 
breast cancer history were excluded because the diagnosis date was not available and the 
diagnosis age was above 45 years.   
 
Covariates   
The risk of delivering a PTB or LBW infant is known to vary by several maternal 
characteristics, including mother’s age at time of pregnancy, race/ethnicity, and socioeconomic 
status (SES).(27–29)  Studies that have focused on disparities in medical treatment and health 
outcomes have demonstrated that racial/ethnic and SES disparities are particularly apparent 
among cancer patients.(30–34)  Therefore, maternal characteristics, race/ethnicity, and SES 
were important covariates to include in this study’s analytical models.  Each covariate included 
in analytical models is described below. 
Preterm birth was defined as gestational age 20 to <37 weeks at delivery.  Infant weight 
was calculated by converting weight in pounds and ounces to grams.  Low birthweight was 
defined as <2,500 grams.  Maternal years of education were categorized as less than high school 
(≤11 years), high school diploma (12 years), at least some or graduated college (13-16 years), and 
professional/graduate degree (≥ 17 years).  Mother’s marital status was abstracted from the 
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birth certificate (married or not married).  Number of living children was used to determine 
parity status as primiparous (i.e., no infant delivery prior to the current birth) or multiparous 
(i.e., a previous delivery in addition to the current birth).  Maternal race/ethnicity is composited 
using the race and Hispanic ethnicity variables on the birth certificate.  Number of cigarettes 
smoked per day during pregnancy was dichotomized as smoked during pregnancy (yes/no).  
Receipt of chemotherapy is derived from the first listed date of chemotherapy treatment or 
otherwise categorized as no chemotherapy.  Length of time between diagnosis and infant 
delivery was calculated using the mother’s breast cancer diagnosis date and the date of infant 
delivery and categorized as <2, 2-4.9, and ≥5 years.  Maternal age at infant delivery in years was 
included in the analysis as a continuous variable.   
 
Statistical Analysis   
Multivariable binomial regression was used to calculate prevalence ratios (PR) and 95% 
confidence intervals (CI) for the association between breast cancer history and birth outcome 
(i.e., PTB and LBW).  We assessed and identified additional covariates as an effect measure 
modifier using likelihood ratio tests (e.g., race/ethnicity) with the a priori significance criteria 
set at 5% or as a confounder using 5% change in estimate tests (e.g., maternal age at infant 
delivery, education, marital status, parity, and smoking) for inclusion in multivariable models.  
We assessed statistical interaction between breast cancer history and race on the additive 
(common referent) and multiplicative (stratified) scales using relative excess risk due to 
interaction (RERI) with 95% CIs (35) and cross-product interaction terms (36), respectively.  All 
analyses were performed using SAS statistical software version 9.3 (Cary, NC).  
 
Results 
Of the 1,912,269 eligible live births in NC during 1990-2009, 512 births were linked to 
mothers with a breast cancer history.  The mean age at breast cancer diagnosis was 31.8 years 
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(SD=4.7) and the average time from diagnosis to delivery was 3.3 years (SD=2.8).  Nearly half 
(49.4%) of mothers with a breast cancer history had a record of starting chemotherapy (Table 
2.1). 
Overall, 10.8% of infants were PTB and 8.8% were LBW.  Among all births, 72.3% were 
to white women and 27.7% to black women.  Compared to the general population of 
reproductive age mothers, mothers with a breast cancer history were older at the time of infant 
delivery, and more likely to have attended college, be married, and not smoke during pregnancy 
(Table 2.1). 
We observed an increased risk of PTB and LBW for births to women with a breast cancer 
history, especially for women who received chemotherapy treatment or gave birth within two 
years of their diagnosis date.  After multivariable adjustment for maternal age, education, 
marital status, parity, race, and smoking, the PR associated with breast cancer history was 1.67 
(95% CI: 1.42-1.97) for PTB and 1.50 (95% CI: 1.23-1.84) for LBW.  The PR of PTB among births 
to mothers with a breast cancer history that received chemotherapy treatment was 2.17 (95% CI: 
1.79-2.63) compared to the general population.  The corresponding PR for LBW was 1.92 (95% 
CI: 1.50-2.45).  The PR of PTB among births that occurred within two years of the mother’s 
diagnosis date was 2.58 (95% CI: 2.12-3.15) compared to the general population.  The 
corresponding PR of LBW was 2.16 (95% CI: 1.64-2.85) (Table 2.2).  
In our data, nearly half of the infants with adverse birth outcomes were both PTB and 
LBW (47.3% overall; 46.6% of births to mothers with a breast cancer history).  Preterm birth 
may be on the causal pathway from breast cancer history to LBW, making co-adjustment for 
these factors inappropriate.(37)  Therefore, we further examined LBW models restricted to term 
pregnancies (≥37 weeks gestation; N=404 births to women with a breast cancer history).  In this 
analysis, the PR for LBW associated with mother’s breast cancer history was 1.68 (95% CI: 1.09 
to 2.59) (Table 2.3). 
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In analyses stratified according to maternal race, the PR for PTB associated with breast 
cancer history was 1.31 (95% CI: 1.00-1.72) for black mothers and 2.06 (95% CI: 1.67-2.54) for 
white mothers.  The corresponding PRs for LBW were 1.49 (95% CI: 1.14-1.94) for black mothers 
and 1.53 (95% CI: 1.12-2.08) for white mothers.  There is evidence of statistical interaction 
between breast cancer history and race for PTB (P-interaction=0.01), but not for LBW (P-
interaction=0.9) on the multiplicative scale (Table 2.4).  The interaction between breast cancer 
history and race was not statistically significant on the additive scale for the risk of PTB (RERI: -
0.61; 95% CI: -1.28-0.07) or LBW (RERI: 0.36; 95% CI: -0.50-1.23).  Compared to white 
mothers in the general population, the PR for PTB was 2.06 (95% CI: 1.67-2.54) for white 
mothers with a breast cancer history, 1.45 (95% CI: 1.44-1.47) for black mothers without a breast 
cancer history, and 1.90 (95% CI: 1.45-2.50) for black mothers with a breast cancer history.  The 
PR for LBW was 1.53 (95% CI: 1.12-2.08) for white mothers with a breast cancer history, 1.82 
(95% CI: 1.80-1.84) for black mothers without a breast cancer history, and 2.71 (95% CI: 2.08-
3.54) for black mothers with a breast cancer history, compared to white mothers without a 
breast cancer history (Table 2.5).  
In analyses restricted to births to women with a breast cancer history, receipt of 
chemotherapy was associated with a PR of 1.78 (95% CI: 1.25-2.53) for PTB and 1.68 (0.94-3.03) 
for LBW compared to no chemotherapy.  The PR of PTB among births that occurred within two 
years of the mother’s diagnosis date was 2.04 (95% CI: 1.44-2.90) compared to births that 
occurred two years or more after the mother’s diagnosis date.  The corresponding PR of LBW 
was 1.78 (95% CI: 0.93-3.41) (Table 2.6). 
 
Discussion 
Women with a premenopausal breast cancer diagnosis may not have started or 
completed their families at the time of diagnosis.  Our findings indicate that a breast cancer 
history may correspond to 50-67% increases in risk of delivering a PTB or LBW infant compared 
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to the general population, with greater increases in risk observed among women who received 
chemotherapy or gave birth within two years of diagnosis.  Examination of the prevalence of 
adverse birth outcomes within race showed that both black and white mothers with a breast 
cancer history had a significant increase in risk (31-49% and 53-106%, respectively) of delivering 
a PTB and LBW infant compared to mothers without a breast cancer history within their racial 
group.  Yet, the prevalence of PTB and LBW was greater for white mothers compared to black 
mothers in these analyses.  This may be due, in part, to the cumulative exposure to risk factors 
for PTB and LBW (38,39) influencing the health status of black women such that the added 
health implications of being diagnosed and treated for breast cancer does not have the same 
level of effect on their reproductive health outcomes as it does for white women.  When white 
mothers in the general population is used as the common referent, white mothers with a breast 
cancer history have the highest prevalence of PTB, but black mothers with a breast cancer 
history have the highest prevalence of LBW.  The interaction between breast cancer history and 
race was significant on the multiplicative scale in the within race analyses when examining PTB, 
but not on the additive scale when white women in the general population was used as the 
common referent.  This attests to the importance of examining racial disparities using a 
common referent other than the white unexposed group.(40)  
Three population-based studies of birth outcomes of women diagnosed with breast 
cancer have been conducted in western Australia, Sweden, and Denmark.(8,16,23)  These 
studies linked cancer and birth data from nation-wide registries, yet have discordant results.  In 
Australia during 1982-2003, 5% (n=123) of women with a breast cancer history conceived after 
their diagnosis, 50% (n=62) of them had a birth within two years of their diagnosis date, and 
only two PTB (<36 weeks gestation) were reported.(16)  In Sweden during 1973-2002, women 
with a breast cancer history (when compared to the general population) had greater odds of 
delivering an early PTB (<32 weeks gestation; aOR: 3.20, 95% CI: 1.70-6.03) or very LBW 
(<1,500 grams; aOR: 2.86, 95% CI: 1.41-5.78) infant.(8)  This increase was not observed in 
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Denmark during 1973-2002, where the odds of delivering a PTB (<37 weeks gestation; aPOR: 
1.2, 95% CI: 0.4-3.8) or LBW at term (<2,500 grams and ≥37 weeks gestation; aPOR: 1.3, 95% 
CI: 0.7-2.2) infant were not significantly different between women with a breast cancer history 
and the general population.(23)   
The magnitude of our effect estimates were consistent with the Danish study (23) and 
used the same cut point for PTB.  The Swedish study (8) used lower cut points for PTB and 
LBW.  We reanalyzed our data using the same cut points as the Swedish study (8), but our 
results were not statistically significant.  The Danish study (23) conducted stratified analyses by 
sex of child and type of treatment, but did not see a substantial change in the overall effect 
estimates.  Our analysis reinforces that racial group is an important consideration for evaluating 
adverse birth outcomes in the U.S.   
Some limitations of our analysis must be considered.  Information on breast cancer 
hormone receptor status, stage, use of endocrine therapy, and chemotherapy agents, dose, and 
cycle were either not available or frequently missing and therefore not analyzed.  We were not 
able to account for multiple births to the same mother.  Pregnancies that result from assisted 
reproductive technology (ART) cannot be identified and tend to have a higher prevalence of 
multiple births, as well as PTB and LBW deliveries.  Only about 1.5% of infants born in the U.S. 
general population are conceived via ART.(41)  
Strengths of our analysis include the use of a population-based dataset to address a 20-
year period with approximately two million births overall.  With persistent racial disparities in 
cancer care and birth outcomes in the U.S., the added exploration of race as a modifier of the 
association between breast cancer history and adverse birth outcomes is an important 
contribution.  Our analyses that examined receipt of chemotherapy and time between diagnosis 
date and delivery provide additional insights into factors along the breast cancer trajectory that 
may contribute to increased risk of adverse birth outcomes among mothers with a breast cancer 
history.  In our data, it is not possible to distinguish pregnancies that co-occur with breast 
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cancer diagnosis or the active treatment period.  Future longitudinal studies that follow breast 
cancer patients from diagnosis to birth will be critical to disentangle potential differences 
between women who are diagnosed with breast cancer during pregnancy from those who 
conceive after the active treatment period. 
Breast cancer treatment has long-term implications on the health and quality of life of 
women.  Understanding the effects of breast cancer treatment on future reproductive health 
outcomes is an important concern for premenopausal women.  They may benefit from targeted 
preconception health services and reproductive health counseling prior to and after cancer 
treatment.  Furthermore, qualitative research may reveal a deeper understanding of breast 
cancer survivors’ decision-making process regarding their treatment regimen as it relates to 
their post-treatment childbearing goals. 
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TABLES 
TABLE 2.1. CHARACTERISTICS OF LIVE BIRTHS ACCORDING TO MOTHER’S BREAST CANCER HISTORY 
AT TIME OF DELIVERY, NORTH CAROLINA 1990-2009  
  Breast cancer 
history (N=512) 
General population 
(N=1,911,757) 
  N % N % 
Preterm Birth      
Term (≥37 weeks gestation)  404 78.9 1,703,476 89.1 
Preterm (<37 weeks gestation)  108 21.1 206,026 10.8 
Missing  0 0.0 2,255 0.1 
Low Birthweight      
Healthy weight (≥2,500 grams)  436 85.2 1,743,325 91.2 
Low birthweight (<2,500 grams)  76 14.8 168,432 8.8 
Missing  0 0.0 0 0.0 
Education      
Less than high school (≤11 years)   19 3.7 266,180 13.9 
High school diploma (12 years)  123 24.0 662,969 34.7 
Some or graduated college (13-16 years)  282 55.1 814,843 42.6 
Professional/graduate degree (≥17 years)  87 17.0 164,664 8.6 
Missing  1 0.2 3,101 0.2 
Marital Status      
Married  404 78.9 1,320,768 69.1 
Not married  108 21.1 590,559 30.9 
Missing  0 0.0 430 0.02 
Parity      
Primiparous (1 birth)  153 29.9 787,261 41.2 
Multiparous (≥ 2 births)  359 70.1 1,124,496 58.8 
Missing  0 0.0 0 0.0 
Race/Ethnicity      
White, non-Hispanic  324 63.3 1,382,978 72.3 
Black, non-Hispanic  188 36.7 528,779 27.7 
Missing  0 0.0 0 0.0 
Smoking      
Non-Smoker  463 90.4 1,605,661 84.0 
Smoker  46 9.0 296,037 15.5 
Missing  3 0.6 10,059 0.5 
Maternal Age at Infant Delivery  
(in years) 
     
Mean (Standard Deviation)  34.6 (4.7) 27.1 (5.7) 
Range  20.0-48.0 18.0-50.0 
Age at Breast Cancer Diagnosis  
(in years) 
     
Mean (Standard Deviation)  31.8 (4.7)  
Range  18.7-44.3  
Chemotherapy      
Didn’t receive chemotherapy  259 50.6   
Received chemotherapy  253 49.4   
Missing  0 0.0   
Length of Time between Diagnosis & 
Infant Delivery 
     
 < 2 years  195 38.1   
2 ≤ years < 5  197 38.5   
≥ 5 years  120 23.4   
Missing  0 0.0   
N=total number; %=percentage 
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TABLE 2.2. PREVALENCE RATIOS AND 95% CONFIDENCE INTERVALS FOR PRETERM BIRTH AND LOW 
BIRTHWEIGHT ACCORDING TO BREAST CANCER HISTORY, CHEMOTHERAPY, AND LENGTH 
OF TIME BETWEEN DIAGNOSIS AND DELIVERY 
 Preterm Birth  Low Birthweight 
  Age Adj. a Multivariableb   Age Adj.a Multivariableb 
N <37 
weeks 
PR  
(95% CI) 
PR  
(95% CI) 
 N <2,500 
grams 
PR  
(95% CI) 
PR  
(95% CI) 
Breast cancer history        
No 206,026 1.00 1.00  168,432 1.00 1.00 
Yes 108 1.89 
(1.60-2.24) 
1.67  
(1.42-1.97)  
76 1.76 
(1.43-2.16) 
1.50  
(1.23-1.84) 
Chemotherapyc        
No 38 1.31 
(0.98-1.76) 
1.17 
(0.87-1.56)  
28 1.28  
(0.90-1.82) 
1.10 
(0.78-1.55) 
Yes 70 2.48 
(2.03-3.03) 
2.17 
(1.79-2.63)  
48 2.24 
(1.73-2.89) 
1.92 
(1.50-2.45) 
Time between 
diagnosis & deliveryc 
       
< 2 years 62 2.86 
(2.33-3.52) 
2.58 
(2.12-3.15)  
38 2.29 
(1.72-3.04) 
2.16 
(1.64-2.85) 
2 ≤ years < 5 30 1.36 
(0.98-1.90) 
1.20 
(0.86-1.66)  
20 1.20 
(0.79-1.82) 
0.98 
(0.65-1.47) 
≥ 5 years 16 1.19 
(0.75-1.87) 
1.04 
(0.66-1.63)  
18 1.79 
(1.17-2.74) 
1.49 
(0.98-2.26) 
Adj.=adjusted; PR=prevalence ratio; CI=confidence intervals 
a Adjusted for mother’s age at infant delivery 
b Adjusted for mother’s age at infant delivery, education, marital status, parity, race/ethnicity, and smoking 
c Includes only women with a breast cancer history (n=512 for preterm and low birthweight) 
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TABLE 2.3. PREVALENCE RATIOS AND 95% CONFIDENCE INTERVALS FOR LOW BIRTHWEIGHT AT 
TERM ACCORDING TO BREAST CANCER HISTORY 
 Low Birthweight at Terma 
  Age Adj.b Multivariablec 
N <2,500 
grams 
PR  
(95% CI) 
PR  
(95% CI) 
Breast cancer history    
No 47,083 1.00 1.00 
Yes 19 2.03 
(1.31-3.15) 
1.68 
(1.09-2.59) 
Chemotherapyd    
No 8 1.57 
(0.79-3.09) 
1.29 
(0.66-2.54) 
Yes 11 2.59 
(1.46-4.58) 
2.14 
(1.22-3.76) 
Time between 
diagnosis & deliveryd 
   
< 2 years 10 3.14 
(1.73-5.70) 
2.93 
(1.63-5.27) 
2 ≤ years < 5 3 0.78 
(0.25-2.39) 
0.60 
(0.20-1.83) 
≥ 5 years 6 2.58 
(1.19-5.61) 
2.12 
(0.98-4.56) 
Adj.=adjusted; PR=prevalence ratio; CI=confidence intervals 
a Infants delivered weighing <2500 grams and at ≥37 weeks gestation 
b Adjusted for mother’s age at infant delivery 
c Adjusted for mother’s age at infant delivery, education, marital status, parity, race/ethnicity, and smoking 
d Includes only women with a breast cancer history (n=404) 
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TABLE 2.4. PREVALENCE RATIOS AND 95% CONFIDENCE INTERVALS FOR PRETERM BIRTH AND LOW 
BIRTHWEIGHT STRATIFIED BY RACE/ETHNICITY ACCORDING TO BREAST CANCER HISTORY  
  Preterm Birth  Low Birthweight  
Race/Ethnicity Breast Cancer 
History 
N <37  
weeks PR (95% CI)a  
N <2,500  
grams PR (95% CI)a 
Black, non-
Hispanic 
No 75,286 1.00 
 
71,159 1.00 
 Yes 40 1.31 (1.00-1.72)  41 1.49 (1.14-1.94) 
       
White, non-
Hispanic 
No 130,740 1.00 
 
97,273 1.00 
 Yes 68 2.06 (1.67-2.54)  35 1.53 (1.12-2.08) 
   
P-interaction=0.01 
  
P-interaction=0.9 
PR=prevalence ratio; CI=confidence intervals 
a Adjusted for mother’s age at infant delivery, education, marital status, parity, and smoking 
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TABLE 2.5. PREVALENCE RATIOS AND 95% CONFIDENCE INTERVALS FOR PRETERM BIRTH AND LOW 
BIRTHWEIGHT BY INTERACTION BETWEEN BREAST CANCER HISTORY AND 
RACE/ETHNICITY 
 Preterm Birth  Low Birthweight 
  Breast Cancer History   Breast Cancer History 
  No Yes   No Yes 
Race/Ethnicity N <37 
weeks 
PR  
(95% CI)a,b,c 
PR  
(95% CI)a,b,c 
 N <2,500 
grams 
PR  
(95% CI)a,b,d 
PR  
(95% CI)a,b,d 
White, non-
Hispanic  130,808 1.00 
2.06 
(1.67-2.54)  97,308 1.00 
1.53 
(1.12-2.08) 
Black, non-
Hispanic  75,326 
1.45  
(1.44-1.47) 
1.90 
(1.45-2.50)  71,200 
1.82  
(1.80-1.84) 
2.71 
(2.08-3.54) 
PR=prevalence ratio; CI=confidence intervals; RERI=relative excess risk due to interaction 
a Adjusted for mother’s age at infant delivery, education, marital status, parity, and smoking 
b RERI = PR11 – PR10 – PR01 + 1; 95% CI for RERI estimated using Hosmer and Lemeshow (35) 
c RERI= 0.61 (95% CI: -1.28-0.07)  
d RERI= 0.36 (95% CI: -0.50-1.23)  
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TABLE 2.6. PREVALENCE RATIOS AND 95% CONFIDENCE INTERVALS FOR PRETERM BIRTH AND LOW 
BIRTHWEIGHT IN WOMEN WITH A BREAST CANCER HISTORY ACCORDING TO 
CHEMOTHERAPY, LENGTH OF TIME BETWEEN DIAGNOSIS AND DELIVERY, 
RACE/ETHNICITY, AND PARITY  
 Preterm Birth  Low Birthweight 
  Age Adj.a Multivariableb   Age Adj.a Multivariableb 
N <37 
weeks 
PR  
(95% CI) 
PR  
(95% CI) 
 N <2,500 
grams 
PR  
(95% CI) 
PR 
(95% CI) 
Chemotherapy        
No 38 1.00 1.00  28 1.00 1.00 
Yes 70 1.86  
(1.31-2.64) 
1.78  
(1.25-2.53)  
48 1.85 
(1.21-2.83) 
1.68 
(0.94-3.03) 
Time between diagnosis 
& delivery  
(2-year cut point) 
  
  
 
  
≥ 2 years 46 1.00 1.00  38 1.00 1.00 
< 2 years 62 2.14  
(1.52-3.00) 
2.04  
(1.44-2.90)  
38 1.84 
(1.22-2.76) 
1.78 
(0.93-3.41) 
Time between diagnosis 
& delivery  
(5-year cut point) 
  
  
 
  
≥ 5 years 16 1.00 1.00  18 1.00 1.00 
< 5 years 92 1.58 
(0.97-2.56) 
1.60  
(0.97-2.64)  
58 1.06 
(0.65-1.73) 
0.92  
(0.54-1.55) 
Race/Ethnicity        
White, non-Hispanic 68 1.00 1.00  35 1.00 1.00 
Black, non-Hispanic 40 1.00 
(0.71-1.42) 
0.97  
(0.65-1.45)  
41 2.02  
(1.33-3.05) 
1.76  
(1.08-2.86) 
Parity        
Primiparous (1 birth) 28 1.00 1.00  22 1.00 1.00 
Multiparous (≥ 2 births) 80 1.27 
(0.86-1.86) 
1.10  
(0.74-1.64)  
54 1.09 
(0.69-1.72) 
0.78  
(0.47-1.27) 
Adj.=adjusted; PR=prevalence ratio; CI=confidence intervals 
a Adjusted for mother’s age at infant delivery 
b Adjusted for mother’s age at infant delivery, education, marital status, parity, race/ethnicity, and smoking 
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CHAPTER 3: THE OTHER SIDE OF THROUGH: YOUNG BREAST CANCER 
SURVIVORS’ SPECTRUM OF REPRODUCTIVE AND SEXUAL HEALTH NEEDS 
FROM DIAGNOSIS TO SURVIVORSHIP 
 
Background 
The long-term reproductive health impact of cancer treatments is a justifiable concern 
for premenopausal women with a breast cancer history.  There are several reasons that a 
diagnosis of premenopausal breast cancer may negatively impact reproductive function.  
Chemotherapy can be directly toxic to ovarian follicles and result in transient or permanent 
amenorrhea, depleted ovarian reserve, and a shorter reproductive window.(1–4)  Indirectly, 
delays in childbearing plans can contribute to an age-related decline in fertility.(1)  For example, 
breast cancer patients are often encouraged to delay pregnancy for at least two to three years 
after diagnosis (1,3), and to not become pregnant during adjuvant endocrine therapy, which may 
be prescribed for five years or more.  Hence, chemotherapy and adjuvant endocrine therapy may 
cause other reproductive health issues due to gynecological and vasomotor symptoms, changes 
in sexual function, and an earlier onset of menopause.(5,6)  Additionally, the potential side 
effects of menopause brought on by chemotherapy and adjuvant endocrine therapy, including 
vaginal dryness and low libido may restrict women’s desire or ability to be sexually intimate with 
their partners.(7,8)  Whether or not women desire to conceive after the breast cancer treatment, 
all premenopausal women may experience treatment-related reproductive or sexual health 
issues that have the potential to affect their quality of life in survivorship.(9) 
A two- to three-year time delay between a breast cancer diagnosis and becoming 
pregnant is recommended because of concern about the lingering toxic effects of cancer 
treatment on growing oocytes and the potential risk of cancer recurrence is highest during this 
period.(3)  However, evidence of the benefit to patients waiting more than two years after 
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diagnosis to become pregnant is limited, especially if the woman has a good prognosis and 
localized disease (10) and the risk of recurrence is low.(3,11,12)  Young women diagnosed with 
breast cancer often question if a pregnancy will increase their risk of breast cancer recurrence 
because breast cancer is hormone-dependent and pregnancy is a period when hormone levels 
are at an all-time high in a women’s reproductive life-span.  The main concern is that an 
increase in hormone levels during pregnancy may stimulate the growth of remaining breast 
cancer cells or dormant micrometastasis, which may in turn increase the risk of recurrence.(3)  
Yet, breast cancer survivors who become pregnant after the completion of treatment tend to 
have the same, if not better survival rates (12–14) and are less likely to experience a recurrence 
of breast cancer (15) than women who do not become pregnant after a breast cancer diagnosis.  
In a study by Gelber and colleagues (13), the overall 5-year and 10-year survival rates for breast 
cancer survivors who became pregnant was 92% and 85%, while 5-year survival was 85% and 
10-year survival was 74% for the matched non-pregnant breast cancer survivor control group.  
The results from the Gelber et al. (13) study are potentially due to a healthy mother effect 
(10,16,17), i.e., women who choose and are able to become pregnant after breast cancer may be 
healthier in general compared to breast cancer survivors who choose not to or are not able to 
become pregnant.(1,16) 
The American Society of Clinical Oncology highly recommends that cancer care 
providers discuss the possibility of infertility and fertility preserving options with their 
premenopausal cancer patients (or refer them to a reproductive specialist) before beginning 
treatment.(18)  Yet, less than half of U.S. physicians are following these guidelines.(19)  It is 
critically important for breast cancer patients to receive information on the potential effects of 
each cancer treatment option on their reproductive and sexual function, so they are fully aware 
of how the treatments may affect intimacy with their partners, as well as plans to begin or 
complete their families.  Receipt of this information will allow breast cancer patients to make an 
informed decision about their cancer treatment regimen and determine if they should receive 
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fertility preservation treatment (e.g., cryopreservation of embryos, cryopreservation of oocytes, 
ovarian tissue cryopreservation, artificial gametes) prior to the onset of cancer treatment.  
According to Resolve, the National Infertility Association, the average cost of fertility 
preservation/infertility treatment ranges from $865 to $8165 per cycle or procedure.(20)  
However, insurance companies usually do not cover fertility preservation or infertility 
treatments (3), which make these options unfeasible for many breast cancer patients who 
cannot afford the out-of-pocket expense for these treatments.   
Preconception health interventions aim to improve the health status and behaviors of 
women (and men) prior to conceiving a child with the ultimate goal of decreasing the risk of 
adverse pregnancy-related outcomes.(21)  The preconception period in the life course often 
refers to the years in which one is of reproductive age, but also recognizes that a woman’s 
preconception health status may be the result of negative exposures in utero or her mother’s (or 
even maternal grandmother’s) lifestyle behaviors or exposures.  Since a majority of pregnancies 
are unplanned, there has been a growing emphasis on promoting healthy behaviors throughout 
the reproductive health period (e.g., smoking cessation, reduction in alcohol use, maintaining a 
healthy weight, consumption of essential vitamins and minerals) and not just during the 
prenatal period.(22)   
There have been national and international efforts to track and improve the 
preconception and maternal health status of women.  The CDC/ATSDR Preconception Care 
Work group worked with a select panel of experts in 2006 to develop a strategic plan that 
provided recommendations on how to improve the preconception health status of women in the 
United States, as well as enhance how preconception care services are rendered.(21)  This call to 
action led to the development of 45 core state preconception health indicators that are now 
tracked via national surveillance systems, such as the Pregnancy Risk Assessment Monitoring 
System.(23)  Furthermore, Healthy People 2020 acknowledges preconception health as an 
important strategy for improving the pregnancy and overall health outcomes of women.(24)  
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The Millennium Development Goal (MDG) framework has expanded MDG5 on improving 
maternal health from solely focusing on maternal mortality to also including reproductive and 
sexual health as important contributors to maternal health.(25)  In general, there is a growing 
recognition that women’s health is much broader than maternal health.  Improving the lives of 
girls and women not only has positive implications for their future pregnancy outcomes (if they 
choose to conceive), but can also enhance their health status and wellbeing in general. 
The preconception healthcare needs of women diagnosed with and treated for 
premenopausal breast cancer may differ from those prescribed to the general population of 
women of reproductive age.  Furthermore, known racial disparities in breast cancer incidence 
rates and birth outcomes raise concerns about potential disparities in the reproductive and 
sexual health outcomes of premenopausal breast cancer survivors since black women are more 
likely than their white counterparts to be diagnosed with breast cancer during their reproductive 
years (26) and experience adverse birth outcomes.(27)  Therefore, it is important to learn about 
the preconception health status and behaviors of special populations (and their sub-groups), so 
that preconception health services for these women can be tailored to suit their specific 
reproductive health concerns that may be magnified by their health condition.    
This study aimed to determine the reproductive healthcare needs of premenopausal 
breast cancer survivors by exploring the concordances and discordances of participant identified 
reproductive and sexual health needs between: 1) women who did/desired and did not have a 
child after their breast cancer diagnosis; and 2) women of color and white women. 
 
Methods 
Institutional Review Board Approval 
The University of North Carolina at Chapel Hill’s IRB and Office of Human Research 
Ethics reviewed and approved this study (#14-1394).  
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Study Design, Approach, and Positionality 
We explored the reproductive healthcare needs of premenopausal breast cancer 
survivors via in-depth semi-structured interviews.  Since reproductive/sexual health and breast 
cancer are sensitive topics and we wanted to explore each woman’s distinct personal experiences 
in order to make comparisons, in-depth interviews were the best qualitative data collection 
method for acquiring the information we needed to address our study’s aim.   In order to build 
rapport with participants, we conducted each interview in-person over the course of two 
sessions. 
The study’s principal investigator (PI) was cognizant that her positionality as a 
researcher was influenced by her race/ethnicity (non-Hispanic black), gender (female), 
educational status (PhD graduate), health status (non-breast cancer patient), and other factors.  
Recognizing that her positionality may affect how she identified subtle and explicit disparities in 
the interview data, she made a conscious effort throughout this study to be aware of her 
preconceived notions, while also carefully listening to what the data was revealing.  Her 
community advisory committee and interviewees were influential in holding her accountable to 
the data.  
 
Community Advisory Committee 
 An advisory committee of two breast cancer survivors and two advocates was convened 
to incorporate a community perspective into the recruitment, data collection, and analyses 
processes.  The committee met during the initial stages of study development and provided 
feedback on the interview guide, as well as recruitment materials and sources.  The committee 
met a second time to discuss and refine the preliminary list of themes.  Two committee members 
attended the group sessions with interview participants and two served as co-authors on this 
paper.  The community advisory committee’s contributions to the development of the study and 
analysis of the data greatly enhanced the overall quality of the study.  Their perspective as breast 
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survivors and long-term advocates allowed them to provide additional insights on the study 
from an experienced lens that the study’s PI did not possess. 
 
Study Population and Recruitment 
From October 2015 to March 2016, the PI recruited women with a breast cancer history, 
diagnosed between the ages of 18 and 45, and living in North Carolina.  An effort was made to 
recruit a racially diverse pool of women with a breast cancer history who had the following 
reproductive health experiences: 1) had a live birth after breast cancer diagnosis; 2) wanted to 
have child(ren) after breast cancer diagnosis, but was not able to become pregnant; or 3) never 
desired to have child(ren) or decided not to have child(ren) after breast cancer diagnosis.   
To identify and connect with young women with a breast cancer history, the PI utilized 
three recruitment sources: 1) community- and cancer center-based breast cancer support group 
meetings; 2) cancer center-based listservs for young breast cancer survivors; 3) referrals from 
the community advisory committee.  At support group meetings, the PI gave a brief presentation 
of the study, disseminated study brochures, and collected the contact information from women 
interested in being interviewed.  Leaders of cancer center-based young breast cancer survivor 
support groups emailed fact sheets about the study via listservs designated for current and 
former support group members.  Community advisory committee members provided a list of 
local foundations for young breast cancer survivors and the PI contacted the foundations via 
email or phone to inform them about the study.  The PI contacted each woman that expressed 
interest in participating in the study, either at support group meetings or via email responses to 
listserv postings, via phone to confirm her interest in being interviewed, collect demographic 
information, determine eligibility, address any questions, and schedule the first interview. 
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Data Collection 
  Each participant was interviewed in-person at a private location that was convenient for 
her (e.g., local library, her home) and the PI conducted all interviews.  All participants provided 
written consent before starting the interview.  Since discussing breast cancer diagnosis and 
treatment, as well as reproductive health may be sensitive topics for some women, we made 
efforts to ensure that the interview questions would cause minimal emotional trauma to the 
participants.  The PI asked the participants if they desired to pause or stop the interview when 
they appeared to be emotionally distressed, but every woman completed the interview.  At the 
conclusion of the first interview, each participant received $25 cash for participating in the 
study, a resource guide of relevant cancer, emotional, and reproductive health support services, 
and a thank you card.  At the conclusion of the second interview, each participant received $35 
cash.  Participant recruitment continued until a saturation point was reached where the 
interviewees’ responses addressed the established questions and began to overlap to the point 
where new insights ceased to surface. 
  We used an in-depth, semi-structured two-part interview guide (Appendix 1).  The 
interview was conducted over two sessions for most of the participants, but three women 
requested to complete the entire interview in one session since it was more convenient for them.  
The first part of the interview lasted on average 35 minutes (Range: 18-66 minutes) and the 
second part lasted on average 57 minutes (Range: 33-99 minutes).  The first part of the 
interview included 24 questions and covered topics such as reproductive history, breast cancer 
diagnosis and treatment story, and reproductive/sexual health experiences around the time of 
diagnosis.  The second part of the interview included 19 questions and inquired more about 
experiences that occurred around the time of their breast cancer diagnosis and treatment, 
including reproductive health information received or desired, met and unmet reproductive 
health needs or concerns, reproductive or fertility issues, and life experiences that may have 
affected their health.  All questions were open-ended.  Many of them included probes to ensure 
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all desired information was captured and to explore participants’ responses more deeply.  The 
questions were asked in sequence; however, those that did not apply to the participant were 
skipped (e.g., questions regarding breastfeeding children post-diagnosis when woman delivered 
all children prior to diagnosis).  Each interview session was audio recorded and professionally 
transcribed.  The PI took notes during each interview session in order to track key information 
that helped guide the interview discussion. 
 
Analysis Approach 
In order to ground the findings in the data, the PI utilized ResearchTalk’s Sort and Sift, 
Think and Shift© method (28), a multidimensional qualitative analysis approach.  The Sort and 
Sift toolbox includes a variety of methods that assist with familiarizing yourself with the data, as 
well as analyzing the data.  These methods include writing memos, monitoring topics in your 
data, inventorying quotations, and diagraming quotations and topics.  This is an iterative 
process of diving in and familiarizing yourself with the data and stepping back to reflect on what 
you learned, so that you can access how to move forward with analyzing your data.  The main 
emphasis is on comparing the experiences of different participants and analyzing each 
participant’s transcript in order to learn about the lived experience of each individual as it 
relates to your research topic.  This allows for the monitoring of topics vertically by participant 
and horizontally across participants. 
This analysis approach along with member checking with the community advisory 
committee and interview participants allowed for the identification of the most salient themes 
that emerged from the data.  Prior to reviewing the data, the PI composed a memo to reflect on 
the interviews with breast cancer survivors and capture what was known so far based on these 
interviews.  This memo captured initial lessons learned from the interviews before she was 
influenced by a deeper read of the transcripts.  Second, she reviewed each transcript, identified 
pulse quotations (i.e., quotations that highlighted the women’s key life experiences and 
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reflections), and wrote a brief memo for each pulse quotation about why it was chosen.  Third, 
after the review of a transcript and identification of pulse quotations, the PI wrote a memo about 
that transcript that addressed two questions: 1) What did we learn from this data collection 
episode?; and 2) Why is this data collection episode important to this study?  Under the first 
question, she composed complete statements that captured the main topics discussed in the 
transcript and placed exemplary quotations under each statement.  Under the second question, 
she wrote a brief memo to describe what was important about the topics discussed in the 
transcript and how the topics addressed the study’s research question.  Fourth, she grouped the 
statements from each transcript memo into key topics.  Fifth, the PI further explored these 
grouped key topics and associated quotations to develop a uniting theme.  Lastly, using matrices 
she explored the grouped key topics to compare the reproductive needs and concerns between 
women who did/desired and did not have a child after their breast cancer diagnosis and women 
of color and white women.   
Since the goal of this research was to learn about the multiple realities and complexities 
of the reproductive health experiences of premenopausal breast cancer survivors, the Sort and 
Sift, Think and Shift© Method was appropriate to use since it allowed for the analysis approach 
to be grounded in the interview participants’ commentary and experiences, while also 
accounting for and compartmentalizing our own biases and preconceived notions.  The PI used 
ATLAS.ti version 7, a qualitative data software package, to manage and organize the data. 
Once we established the key themes, the community advisory committee and the 
interview participants were invited to separate group sessions to discuss the preliminary 
findings.  The first group session was with the community advisory committee and was an 
opportunity for the PI to garner their feedback on the themes that emerged from the data.  From 
this discussion, we determined the most relevant themes to explore further, specifically the 
themes that addressed the original intent of the study.  The second group session was held in-
person with the interview participants, in which four of the 17 attended.  During the discussion, 
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the participants’ provided their feedback on the emergent themes confirmed by the community 
advisory committee and exemplary quotes, as well as share any additional insights.  This 
discussion was audio-recorded in order to capture all participants’ comments, but not for 
analysis purposes.  The PI used the feedback from the community advisory committee and the 
participants to determine which themes resonated most with the community and to enhance the 
wording and presentation of the themes and participants’ quotes. 
 
Findings 
 Details regarding the characteristics of the 17 study participants with a breast cancer 
history are provided in Table 3.1.  The mean age at first breast cancer diagnosis was 38.6 years 
and the mean age at the time of the interview was 45.8 years.  This group of women was highly 
educated; all of them had at least some college education.  At the time of the interview, a 
majority of them were married or engaged (n=13), had two or more children (n=11), and never 
smoked (n=14).  Twelve of the women gave birth to all of their children prior to their breast 
cancer diagnosis.  Yet, one had all of her births occur after her diagnosis, two had births before 
and after their diagnoses, and two did not have any children.  Ten of the women identified as 
white, non-Hispanic and seven of the women identified as women of color (e.g., black/non-
Hispanic, Asian, Latina).  In regards to breast cancer stage, 14 had invasive (stage 1-3) breast 
cancer.  Most of the women had a lumpectomy (n=12), received chemotherapy (n=11), did not 
receive breast reconstruction (n=12), and received adjuvant endocrine therapy (n=14).  Two of 
the 17 women experienced a breast cancer recurrence, including one woman that was diagnosed 
three times over a 12-year period with the second diagnosis occurring during a pregnancy.  
Additionally, one woman was diagnosed with melanoma a week after her breast cancer 
diagnosis and was treated for both at the same time. 
Five overarching themes emerged from the data that shed light on the spectrum of met 
and unmet reproductive needs identified by women with a breast cancer history (Table 3.2).  
 54 
The five themes are: 1) women received limited reproductive health information from their 
cancer care providers; 2) medical providers often told the women that they would not be able to 
have children after cancer treatment and did not give an honest depiction of the feasibility of 
conceiving post-treatment; 3) having a family history of breast cancer influenced women’s and 
their family members’ decision-making about their cancer treatment and lifestyle choices; 4) 
most women who received breast reconstruction struggled with adjusting to their altered 
physical appearance, which affected their body image; and 5) the menopause symptoms caused 
by chemotherapy, adjuvant endocrine therapy, and hysterectomies led to sexual health issues 
that affected the women’s intimacy with their partners and quality of life.  Despite the many 
commonalities in these women’s experiences, there were differences between women who 
did/desired and did not have a child after their breast cancer diagnosis, as well as between 
women of color and white women.  The concordances and discordances in the reproductive 
health needs of women with a breast cancer history are described below and selected quotes are 
exhibited in Table 3.2. 
 
Theme 1: Received Limited Reproductive Health Information 
 Concordances.  The extent of the reproductive health information that a majority of 
the women received from their cancer care providers was limited in nature and did not 
comprehensively address their concerns.  Most women learned from their providers that 
chemotherapy and adjuvant endocrine therapy treatment might impair their fertility or cause 
the early onset of menopause.  Providers urged women with hormone receptor-positive tumors 
to not become pregnant in order to decrease the risk of cancer recurrence and to not take 
hormone-based contraception.  Although the women learned about what not to do, they did not 
receive sufficient advice about how to manage menopause symptoms or prevent pregnancy.  
Furthermore, women felt that if they were of advanced maternal age or expressed that they did 
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not want to have any more children, their cancer care providers assumed they were not 
concerned with reproductive health issues and therefore provided limited education in this area. 
 Pregnancy prevention during breast cancer treatment was a particularly challenging 
issue for women who used hormone-based contraception methods (e.g., intrauterine devices, 
birth control pills) prior to their breast cancer diagnosis.  Their providers advised them against 
becoming pregnant at all or at least not during treatment, including during adjuvant endocrine 
therapy.  Yet, many of the women did not receive recommendations on which contraception 
methods to utilize and there seemed to be an underlining assumption that their only option was 
condoms.  When asked if her cancer care providers recommended she use contraception, a 
survivor of color (Age 45 at diagnosis; no children) responded, “No, the only thing he said was 
just don't get pregnant right now.”  When asked what type of conception she uses, she said, 
“None really.”  This response was concerning especially since this woman was actively going 
through treatment and other women had similar responses when asked about their 
contraception usage during and after their breast cancer treatment.  In fact, only one white 
survivor (Age 40 at diagnosis; 2 children pre-diagnosis) shared that her provider suggested her 
husband receive a vasectomy.  This was a suitable option for this woman since she had reached 
her ideal family size and it was a highly reliable solution to preventing pregnancy during her 
treatment and beyond.  Yet, it is alarming that more women did not receive adequate counseling 
on their contraception options, especially since the potential fetal health complications and 
increased risk of cancer recurrence associated with pregnancy during or within a short interval 
after cancer treatment completion. 
As reproductive health-related issues arose during their breast cancer journeys, the 
women felt their cancer care providers provided limited information and did not address their 
array of concerns.  They relied on their obstetricians/gynecologists (OB/GYNs), support groups, 
Dr. Susan Love’s Breast Book (29), and the Internet to fill the gaps in their breast cancer-related 
reproductive health education.  The women felt that their OB/GYNs specialized in reproductive 
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health and were better equipped to address their specific concerns that ranged from vaginal 
dryness to the pros and cons of hysterectomies.  In addition to discussing their concerns with 
their providers, these women valued conversations they had with other breast cancer survivors 
since they directly experienced and understood their challenges.  A white survivor (Age 40 at 
diagnosis; 2 children pre-diagnosis) shared that her favorite resource was her support group: 
“I guess because you’re talking to people that have actually gone through it.  Talking to a 
male doctor about hot flashes, it’s not really – he’s like, ‘Oh, yeah, it could happen 10 to 
20 times a day.’  And I thought, ‘Oh, yeah, ‘cause that’s no big deal.’  Easy for him to say, 
‘cause he’ll never experience anything like that.  I find it more comforting to talk to other 
women that have been through it.”   
 
She felt that she was able to relate to other survivors since they shared a common experience 
and that male providers were limited in their ability to convey the magnitude of menopausal 
symptoms since they would never experience them.  A survivor of color (Age 37 at diagnosis; 2 
children post-diagnosis) did not remember receiving much reproductive health information 
from her cancer care providers.  However, after being introduced to Dr. Love’s book, it became 
her go-to resource: 
“Yeah.  I think Dr. Love's book was great.  And I think talking to people – I have just 
found out by accident I have neighbors who had breast cancers.  She's much older…  But 
I remember… she's the one who told me about the book…  I thought [Dr. Love’s book] was 
very comprehensive.”   
 
Other women displayed the same resourcefulness and sought out information to address their 
reproductive health concerns via their OB/GYNs, other breast cancer survivors, and books on 
breast cancer. 
Even though many women received advice to not conduct searches on the Internet, some 
women felt that the Internet was a more readily available resource than their cancer care 
providers.  A white survivor (Age 33 at diagnosis; 1 child pre- and 1 post-diagnosis) explained: 
“People run to the internet.  They rely on the Internet so much.  You can hand someone a 
piece of paper, but it's going to get stuffed in the bottom of their purse, depending on how 
busy they are, or at the foot of their car, or maybe even end up in the trash as they walk 
out the door.  The person themselves, if they're really interested in it, is going to research 
it themselves.”  
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She remarks on the inevitably of women utilizing the Internet as a resource and how easy it is to 
misplace a brochure that a provider may give you.  Another white survivor (Age 39 at diagnosis; 
1 child pre-diagnosis) discussed her disagreement with discouraging breast cancer patients from 
using the Internet.  She exclaimed: 
“There wasn’t just a ton of resources around …reproductive health in general, either on 
the fertility side or the sexual functioning side.  …So, I did a lot of my own research.  And 
one of the things that I think has been so weird to me, …all the women are in the support 
groups, telling each other to stay off the Internet.  I'm like, ‘Why are we telling each other 
to stay off the Internet?’  Like that's where all the great information is.  Yes, there's crap 
out there, but if you're a reasonably intelligent adult, you can filter through what's crap, 
what is one person's experience versus what is more valuable information I think.  
Anyway, so that drives me a little crazy about the culture of breast cancer; we're not 
supposed to be on the Internet.  But going on the Internet helped me get a more balanced 
picture from different resources of what I might be looking at.  …More of the spectrum of 
that experience rather than, ‘Here's all the awful things that are probably gonna happen 
to you, so get ready.’” 
 
She sheds light on how breast cancer patients are receiving limited reproductive health 
information from their providers, so the Internet is the obvious resource to access in order to 
address their concerns. 
 Discordances.  The women interviewed shared similar experiences regarding the lack 
of comprehensive reproductive health information received.  Yet, there were some discordance 
by post-diagnosis birth status and race in regards to proposed fertility preservation options, 
cancer treatment decision-making, sources of reproductive health information, and level of 
comfort discussing reproductive health issues with providers. 
 Women who desired to have children after completing cancer treatment, particularly 
women of color, were more proactive in choosing the least invasive treatment options in order to 
preserve their fertility options.  One survivor of color (Age 37 at diagnosis; 2 children post-
diagnosis) received a Lupron shot to suppress her ovaries during treatment and preserve the 
option for her to conceive post-treatment.  Another survivor of color (Age 45 at diagnosis; no 
children) sought out treatment from a specific cancer center that offered her the least invasive 
treatment route, so that she could preserve her fertility after the first cancer center where she 
 58 
was diagnosed was pushing a more aggressive treatment approach.  When asked about what she 
had learned about the potential effect of cancer treatment on her reproductive health, a survivor 
of color (Age 40 at diagnosis; 2 adopted children pre-diagnosis) responded: 
“Overall is that it could kill your fertility issues.  There were things that you could do 
definitely to preserve your fertility, but it just seemed like it would take away from – at 
the time your main focus is just taking care of the cancer, and it seemed like preserving 
your fertility just took time away from that in my mind.  That's why it kind of pushed it 
to the back burner.”   
 
She had undergone multiple fertility treatments prior to being diagnosed and knew the time and 
effort that process takes.  She was not willing to delay her cancer treatment in order to pursue 
fertility preservation options.  Although some of the white survivors advocated for young breast 
cancer survivors choosing treatment options to preserve their fertility if they wanted to conceive 
later, none of these women personally chose less invasive treatment options with the intent of 
preserving their fertility. 
 White women mentioned more often that they attended cancer center-sponsored 
support groups and workshops that shared reproductive and sexual health information.  They 
also expressed a different level of dissatisfaction with the reproductive information they 
received.  A white survivor (Age 42 at diagnosis; 2 children pre-diagnosis) shared:  
“It was only discussions at group about people that had concerns with intimacy or side 
effects of some of the drugs.  Nothing specific was given to me.  I just had exposure from 
the women around me, not from a doctor or a nurse.”   
 
Another white survivor (Age 45 at diagnosis; 1 child pre-diagnosis) commented on the 
reproductive health education she received: 
“I didn't really have any counseling.  The oncologist spoke with me about it, my 
[obstetrician] has, and then after treatment we had at least one class and they have them 
on occasion, in the [cancer center workshop series] that kind of talked about maybe not 
necessarily reproductive, but your intimacy and sexual intercourse after the treatment 
and that kind of thing.  Not necessarily your menopause or ability to have children or 
any of that, but more of the fun part of it.”   
 
None of the survivors of color mentioned utilizing these cancer center-sponsored support 
groups and workshop series.  The survivors of color were more involved in community-based 
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cancer support groups and one even established a local foundation for young breast cancer 
survivors.  White survivors expressed how their cancer care providers did not seem comfortable 
discussing reproductive health topics and the information that was shared painted a 
disheartening perspective of their post-treatment sexual health outcomes.  A white survivor (Age 
39 at diagnosis; 1 child pre-diagnosis) in active treatment exclaimed:  
“They gave me a book at the cancer center, which is a great book.  It's all about 
treatment and side effects, and there was a section about reproductive health and 
sexuality.  And it painted a very dark picture, honestly.  It was like, ‘Your libido is gonna 
go away.  You're not gonna be interested.  You're not gonna be capable.’  I was like, ‘This 
is awful.’  There was a very negative perspective.”   
 
When asked about her concerns regarding the effect of cancer treatment on her reproductive 
health, she shared: 
“Yeah, that was one of my actually biggest concerns about the whole thing.  …my 
oncologist…he's great.  He actually draws pictures and writes everything down so you 
have something to take away.  It's really a wonderful approach.  But he's listing side 
effects and he's like, ‘Hair loss and nausea, but here's what we're gonna do.’  And I had to 
actually ask, ‘Is this gonna kick me into menopause?’ …just wasn't even brought up as a 
concern, like it was not as important.  But I was super concerned about it.  Anything that 
I've learned about what kind of impact is this going to have reproductively or sexually 
has just been independent study. …And I just felt like there wasn't good information 
about that.  It's hard to get the doctor to talk about it.”  
 
Her comments suggest that cancer care providers are good at explaining the general side effects 
of cancer treatment, but are not well prepared to convey how treatments may affect women’s 
reproductive and sexual health or how they can manage these side effects.  Furthermore, she 
conducted her own research to address her reproductive and sexual health concerns since it was 
so difficult to discuss these concerns with her cancer care providers.  Although survivors of color 
recognized the limitations of the reproductive health information they received, none of them 
expressed the level of discontent that the white survivors openly shared. 
 
Theme 2: Desired Realistic Expectations of Conceiving Post-Treatment 
Concordances.  The breast cancer journey made several women reflect on 
childbearing.  Women who had completed their families were thankful they had reached their 
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ideal family size prior to their breast cancer diagnosis.  A survivor of color (Ages 29 & 37 at 
diagnosis; 4 children pre-diagnosis) reflected on what she would have done if she had not 
reached her ideal family size at the time of her diagnosis: 
“Had I not had my tubes tied and had the kids, I definitely would've been concerned, and 
probably doing everything that I could to have kids, 'cause that's just something that was 
very important to me.  Even, like, my girl did, I would’ve tried to freeze eggs, doing 
something.  Even with my friend that was told she couldn’t have [kids], that just 
would've have been enough for me – I would've just probably tried to do anything that I 
could.  I read people all the time that's gone through cancer and still able to have 
children.  …I'm just thankful for the time that – you know, of course, I hate that I had to 
go through cancer, but thankful that I was able to complete my family, with my four, 
before I had to go through it.  Especially since, you know, as soon as I did, the doctor 
said, ‘I don't think you should have anymore.’” 
 
Having children was extremely important to her and she was grateful to give birth to all of her 
children because her doctor recommended that she not bear any more children after treatment.  
Similarly, when asked if the negative reproductive health effects of breast cancer treatment 
affected her family completion goals, a white survivor (Ages 28, 37, & 40 at diagnosis; 1 child 
pre-diagnosis and pregnant with 1 child at second diagnosis) responded: 
“I don't know.  I think I told you last time I may have had another child if I hadn't gotten 
cancer again.  But like I said, I'm happy with what I have, and I feel blessed to be able to 
have them.  So, I don't really know how to answer that question, 'cause it's possible that I 
would have had another child, but I try not to think about it too much.  You know?  And I 
just, like I say, I'm a glass-half-full kinda girl.  So, I'm just as happy, and I feel blessed 
that I have what I have.”   
 
Women who wanted to, but were not able to have children after their treatment made 
peace with their circumstances.  A survivor of color (Age 40 at diagnosis; no children) 
articulated: 
”My journey is an ongoing journey and I don't regret anything that I have been through 
my journey, even though it is to the point that I will never, ever be able to have children.  
I am okay with that; I came to an agreement and an understanding and it is okay, 
because I have other kids that I can love like my nieces and nephews and godchildren.”   
 
Even when coming to terms with not being able to bear any more children after completing 
treatment, some women still felt remorseful of this situation.  When asked if being diagnosed 
 61 
with breast cancer influenced her ideal family goals, a white survivor (Age 40 at diagnosis; 2 
children pre-diagnosis) exclaimed:  
“It didn’t, but I do remember it making me think I guess.  I mean I thought I was done 
anyway, but you know what I mean?  I don’t know how to explain it, but at 40 people do 
have babies in their 40s.  So, I mean yeah I guess I thought about it, but luckily I had my 
two boys, and they were what I wanted.  Yeah it just made it more final I guess.  It just 
made me think about the fact that that door was closed, whereas before it wasn’t closed.  
I mean it was closed by me I guess mentally, but it wasn’t totally closed.  I mean you 
think about a lot of stuff when you’re going through cancer.  So it was just one of the 
things.”   
 
Going through breast cancer made several of the women realize that their childbearing years 
had come to an end even though it was earlier than anticipated. 
 A few women remained hopeful that they would be able to conceive after treatment.  One 
survivor of color (Age 45 at diagnosis; no children) and was still in active treatment said:  
“Well, ideally I wanted to have two children, a boy and a girl, but I do come from a large 
family, so my thing was whatever I was blessed with, that's what I would do.  But 
ideally, that was my desire and I still have not totally given up on that.  Even though 
right now while I'm on the Zoladex and Anastrozole, the doctor says not to get pregnant 
because that could be potentially harmful for a fetus and with all of the other stuff that 
I'm taking, they don't know.  So right now, I'm not actively trying to conceive, but that 
was one of the things early on that we had talked about that… I wanted to preserve that 
option because even though I recognize with my age that it presents some health risk for 
my age…  And it has been posed to me to look into adoption, but I won't say it hasn't 
crossed my mind, but that's not my desire right now.  I wanted to at least leave the 
possibility open to preserve that, so that's my right to choose whether or not to do that.” 
 
Despite her age, she chose the least invasive treatment route, so the possibility of conceiving 
remained an option for her.  Women who were years past treatment were still keeping their 
childbearing options open.  A white survivor (Age 42 at diagnosis; 2 children pre-diagnosis) 
shared: 
“My husband and I always said we would have two or three children and as far as we're 
concerned, we're pretty much done, but…there's always just that little bit that, I don't 
know for sure…  Mentally, I think I'm done, but physically I think we're both still 
capable.  Just emotionally, and professionally, and the ages of our kids and stuff, I think 
it's a done deal, but mentally, I think I'm at the normal stage for a woman my age that 
you go, ‘Oh, I'm about to be done for good.’”   
 
Some women possessed a glimmer of hope that they would be able to have children after 
treatment, but the combined reality of their advancing age and the potential effect that cancer 
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treatment may have had on their reproductive health made them face the inevitability of their 
reproductive years coming to an end. 
Discordances.  The time of treatment is a crucial decision-making period, particularly 
for women that desired to conceive after the completion of their breast cancer treatment.  
Unfortunately, several women shared that they were not well supported by their providers (e.g., 
cancer care team, obstetricians/gynecologists [OB/GYNs]) in their goals to preserve their 
fertility or carry out a pregnancy.  Among the women who desired to conceive or did bear 
children after treatment, there were distinct differences in how the survivors of color versus the 
white survivors discussed their challenges conceiving after treatment.   
The survivors of color discussed not receiving much guidance from their providers on 
how long they should wait after treatment before trying to conceive.  One survivor of color (Age 
37 at diagnosis; 2 children post-diagnosis) had it set in her mind that she would try to conceive 
six months after completing her treatment, even though it is typically recommended that women 
with breast cancer wait two to three years after diagnosis before becoming pregnant.  Reflecting 
on how quickly she became pregnant with her first child post-treatment, she said: 
“I was surprised, actually, how easy I conceived our daughter.  'Cause I was – I don't 
know, I just think that – You know, I wasn’t very young; I was 38.  I just thought it was 
gonna take – it's going to take a while.  But I think – yeah, I think we – I got pregnant 
after a couple of months.”   
 
She had stage 1 breast cancer and her oncologist did approve of her becoming pregnant.  Her 
providers were more concerned about her age than her breast cancer status in regards to her 
pregnancy outcomes.  A survivor of color (Age 40 at diagnosis; no children) was less lucky in 
being able to pursue her childbearing goals after treatment.  Even though she had in situ breast 
cancer, her treatment included multiple biopsies, two lumpectomies, a mastectomy, and TRAM 
(i.e., stomach) flap breast reconstruction all in one year.  The following year she was diagnosed 
with multiple uterine fibroids, which resulted in a hysterectomy.  It was then she knew that her 
“chances of giving birth [where] no more.”  Her dreams of having children abruptly came to an 
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end after reproductive and chronic health issues impaired her ability to conceive.  She and other 
women discussed how they were not emotionally prepared for losing their capability of 
conceiving children after treatment.  This reality was particularly challenging for women who 
did not have any children. 
One white survivor (Age 33 at diagnosis; 1 child pre- and 1 post-diagnosis) experienced 
both the benefits of provider support and the challenges with provider discouragement in 
regards to becoming pregnant after treatment.  She was the only woman to report that her 
oncologist fully educated her about her reproductive health and fertility options even though she 
told him that she was not planning on having any more children.  Regarding the usefulness of 
the reproductive health information she received from her oncologist, she stated: 
“I think it was great.  I mean not useful because we weren't planning to have children, 
okay.  So, I mean I don't want to say I used the information.  But when I got pregnant, I 
was like, ‘Oh my goodness, I remember what he said.  This could be really bad.’  And so I 
saw a specialist because of the cancer.  I had the gestational diabetes.  I was one of those 
people I was like, ‘Okay, I remember the oncologist saying this could come out really 
bad,’ and so me and my husband just talked about it.  If something was wrong with the 
baby, what would we do, and that's 'cause we remembered everything he said.” 
 
Although she believed that she did not need the fertility education at the time and most of the 
information she received focused on the potential negative outcomes, she found the information 
she received from her oncologist to be extremely useful once she unexpectedly became pregnant.  
What she learned from him prompted her to seek the proper care during her pregnancy and her 
oncologist was very supportive and happy for her and her husband once she became pregnant.  
However, once she was under the care of her OB/GYN specialists the provider support ceased.  
She stated: 
“Because of my age, cancer, and then right away, like as soon as I found out I was 
pregnant I went to the doctor.  They gave me that gestational diabetes test; I failed it 
right then and there…  Like I was diabetic; it was terrible.  The lady said to me…, ‘The 
chances of this being successful for you and the baby are very small.’  She was just like, 
‘By 32 weeks, I expect to have you induced, in the hospital, and having a premature 
baby.  …You've just gone through cancer treatment, so your body has been chemo-
infused.  I don't know how strong your body overall, if it can even carry a baby that 
long.’  And she's like, ‘You already have gestational diabetes, which means the baby's 
probably going to be fairly large, and I don't think you're going to be able to carry.’  And 
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so I left that doctor's office just pure crying my eyes out.  I went home, I told my 
husband…, ‘I'm just not going to be able to carry this baby.  She's going to die.  She's 
going to come out sick.’  And I made it 39 weeks.  Absolutely healthy.”  
 
Her OB/GYN team was pessimistic about her potential pregnancy outcome and painted a 
discouraging picture of what to expect.  She ultimately had an inconsequential pregnancy and 
delivery, but experienced great anguish from their predictions.  She feels they should have 
provided her with the full spectrum of possibilities and not just the negative outcomes.  She 
hoped these providers learned from her situation that it is possible for breast cancer survivors to 
have healthy babies.  Once she had her child and went back to her cancer providers for check-
ups, she felt her surgeon and radiation oncologist lacked the experience and bedside manner to 
deal with a lactating patient.  She exclaimed: 
“...the whole pregnancy, lactation, breast cancer thing, they had no experience with.  
‘We've not had lactation patients in here.  This does not happen.’  They weren't against it, 
but I just think it was so out of – they didn't know what to do.  They were blushing.  
…Like the one doctor, the surgeon, didn't want to do the mammogram; he just did an 
ultrasound for the first year.  …even though I'm still breastfeeding, he feels like it's 
further along, like it's not going to be as detrimental to the breast.  He wouldn't even 
touch it.  He was, ‘It's working.’  I mean he was like just, ‘Cover up. Do you need more 
paper towels?’  …and then when they palpate the breast, they don't know the difference 
between a lactating with all the milk ducts full, so to them, it does not feel like an okay 
breast.  And that's because they're not used to feeling one that has got the full milk ducts 
in it.  So, I mean the lack of experience on that, and everyone was like, ‘I don't know what 
to do; I'm sorry.’” 
 
Her cancer care providers’ lack of comfort examining a lactating patient made for an awkward 
situation that negatively influenced her relationship (and potentially trust) with these providers.  
Many women were able to make peace with not being able to conceive after treatment, 
especially if they were already approaching the end of their reproductive years at the time of 
diagnosis.  Yet, women who desired to have children or were in their prime reproductive years 
needed support from their cancer care providers and OB/GYNs to successfully attempt and 
carry out their post-treatment pregnancies.  Furthermore, they wished to have a more 
comprehensive and balanced depiction of their ability to successfully conceive after treatment.  
A focus on the potential negative outcomes did not provide a sense of encouragement or hope to 
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women who had already survived breast cancer, but still wanted to bear children.  This attests to 
providers’ lack of knowledge and experience with women who successfully conceive and deliver 
children after breast cancer treatment. 
 
Theme 3: Family History of Breast Cancer Influenced Lifestyle Choices 
Concordances.  As expected, some women had strong family histories of breast cancer 
and others were the only person in their family to be diagnosed.  When asked about her family 
history of breast cancer, a white survivor (Age 45 at diagnosis; 1 child pre-diagnosis) said, “Zero.  
I am the history.”  One survivor of color (Age 40 at diagnosis; 2 adopted children pre-diagnosis) 
was the only participant who had a positive BRCA gene mutation result and she did not have any 
blood relatives that had been diagnosed with breast cancer.  Even though she had a life long 
struggle with infertility, she felt grateful that she did not have any biological children to pass on 
this gene mutation.  However, among the women that did have a strong family history of breast 
cancer, there seemed to be a trend where the older generations were diagnosed at age 50 and 
above and the younger generations were being diagnosed at much younger ages.  Despite these 
similar cancer history patterns, the survivors of color and white survivors responded in different 
ways to this knowledge about the lack or strong occurrence of breast cancer in their families. 
 Discordances.  Knowing an immediate or distant family member that had breast 
cancer either encouraged women to take preventive measures or discouraged them out of fear of 
being diagnosed.  One survivor of color (Age 40 at diagnosis; 2 adopted children pre-diagnosis) 
did not have a family history of breast cancer, but when she was sixteen her aunt by marriage 
was diagnosed and died of breast cancer at age 40.  She was eager to start getting mammograms 
at age 40 and was diagnosed with breast cancer as a result of her first mammogram.  This 
eagerness and awareness prompted by the death of a loved one resulted in her getting diagnosed 
early on in the development of her breast cancer.  Having a breast cancer role model, such as a 
mother or aunt, made some women less distressed about treatment and more focused on 
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survivorship since they have seen someone live through breast cancer.  A white survivor (Age 39 
at diagnosis; 1 child pre-diagnosis) whose mother had breast cancer stated:  
“And I think for me, I was not totally shocked to be diagnosed, 'cause my mother was 
diagnosed at a relatively young age, and I watched my mother go through treatment.  
So, I think I had sort of an innate sense that you can come through this and come out 
okay, 'cause she's now 60-whatever-she –is.  You know?  And she's happy, and she dates, 
and she has a – she's a registered dietitian, and… She's totally fine.  So, I had a very clear 
role model of, ‘You can come through this,’ and it will be terrible' 'cause it was, ‘and still 
have a great life on the other side of it.’  So, I think I was more concerned about not, ‘Am 
I gonna die,’ but, ‘What is the quality of life that I'm gonna experience, and what does 
that look like?’  So, I wonder if that makes me a bit of an outlier.  I didn't have the same 
sort of cancer terror that I think some people will have.” 
 
Her mother showed her that living through cancer was possible, so she was able to see through 
to the other side of her journey and think about life after breast cancer.  Her mother’s breast 
cancer experience also influenced her treatment decisions.  She was in the midst of 
chemotherapy treatment and was still determining which surgical route she would take.  She 
explained why she was leaning towards undergoing the least invasive treatment option: 
“I think I'm intimidated by the prospect of reconstruction for mastectomy.  My mother 
actually had a mastectomy and then had it reconstructed and it was a long process.  I'd 
rather they just do nothing.  I'm like, ‘What's the least invasive choice?’  Another thing is, 
they can't uncut.  If they do a lumpectomy and there's issues or something, you can 
always go back and have more taken off, but they can't really undo that, so less cutting it 
good I think.”   
 
She approached her treatment with a sense of awareness of how each decision she made would 
affect her quality of life. 
 Survivors of color described being motivated to get mammograms since they knew 
someone who had breast cancer and they prepared their daughters to do the same.  A survivor of 
color (Ages 29 & 37 at diagnosis; 4 children pre-diagnosis), who established a breast cancer 
foundation for young survivors, described how she would take her daughters to breast cancer 
events with her.  She wanted them to see what she went through and be well informed once it 
was time for them to begin getting mammograms.  Some white survivors shared that their 
strong family histories of breast cancer caused their daughters and nieces to live in fear of being 
diagnosed with breast cancer themselves.  One white survivor (Age 42 at diagnosis; 2 children 
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pre-diagnosis) shared that one of her daughters was hypersensitive to being diagnosed with 
breast cancer since in addition to her mother being diagnosed with breast cancer, her father’s 
mother and sister both died from it.  Her daughter sought out genetic testing and did not have 
the BRCA gene mutation, but she remained terrified that she would be diagnosed as well.  
Another white survivor (Age 42 at diagnosis; 2 children pre-diagnosis) had nieces in their 
twenties who were making lifestyle decisions based on their strong family history of breast 
cancer, which included their maternal great grandmother, maternal grandmother, paternal 
great-great aunt, maternal great aunt, and maternal aunt (the interviewee).  She explained how 
her nieces responded differently than her and her sisters to their family breast cancer history by 
sharing: 
“I've got a few nieces that have told me that [they are] exercising and running half 
marathons and doing things that me and my sisters, none of us are exercise anything…  I 
feel like I'm active, but I don't do structured exercise.  And my sisters are the same way, 
but some of our nieces are not doing that at all.  They're Fitbit wearers… and part of the 
reason they do that is because they're worried.  And one of my mother's sisters is more 
healthy, health driven, more nutrition conscious.  And she's never had a breast cancer 
diagnosis…  So, I think whether conscious or subconsciously, the younger girls are 
watching it and going, ‘Oh, Aunt [A] never had anything, and she's the more health 
conscious overall.’  And so, I think they've taken that to heart.  So, they have made some 
lifestyle decisions.  …like it's hardwired in [them], ‘What can we do to make ourselves 
healthier by what we eat?’…And I think it is partially because of the cancer stuff in our 
family.” 
 
While the younger generation in her family was very health conscious in an effort to prevent 
breast cancer, her generation was less apt to engage in breast cancer prevention activities.  Her 
nieces also sought counsel from her about whether they should delay graduate school to have a 
family or stop taking birth control to reduce their risk of breast cancer.  The assumed high risk 
of breast cancer was affecting all areas of her nieces’ lives and this greatly concerned her because 
she did not want them to live in fear of this disease or let it unnecessarily dictate their lives.  This 
sense of fear of the inevitable was very apparent in the stories shared by some white survivors, 
but not in those of the survivors of color. 
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Theme 4: Struggled with Adjusting to Altered Physical Appearance 
 Concordances.  There was a general consensus among the women’s stories that breast 
reconstruction did not meet their expectations and they struggled with adjusting to their altered 
physical appearance.  Many of the women felt that the implants could never be satisfactory 
replacements for the breast(s) they lost.  A white survivor (Age 42 at diagnosis; 2 children pre-
diagnosis) reflected on her breast reconstruction process and stated: 
“I think just the scars and the implant process.  It doesn't feel – you don't feel like 
yourself there after the implants.  You know.  And especially during the expander part, it 
feels very foreign and they're very hard.  And every time you breathe, it's a reminder 
that there's something fake going like this every time you breathe.  And then they put the 
implants in, and it's much better, but it still doesn't feel like you used to.” 
 
The implants served as constant reminders of their breast cancer experience and what was lost 
in the process.  After undergoing breast reconstruction and living with the results, some women 
regretted getting implants.  A survivor of color (Age 34 at diagnosis; 1 child pre-diagnosis) 
shared her regrets about getting breast reconstruction: 
“Sometimes I say if I could go back and change some things about my journey, that may 
have been one of the things that I would've done, is just kind of let it be.  Um-mm. you 
know, because there's so many prosthesis and apparatuses and you know.  Just like you 
can't look at me today and tell, I don't think anybody would've been able to look at me 
and tell otherwise either.”   
 
With the variety of prosthesis and apparatus options, some women felt that breast 
reconstruction was not always necessary.  Yet, the widespread dissatisfaction with breast 
reconstruction was centered in the women not being well prepared about what to expect from 
their new implants.  It seems they wanted and needed clear expectations to be set by their 
cancer care providers about the breast reconstruction process.  One white survivor (Age 42 at 
diagnosis; 2 children pre-diagnosis) even sought out this information from her providers and 
obtained a series of pictures of the breast reconstruction process (from post-operation through 
the healing process) that a breast cancer patient created and published.  However, information 
of this caliber is not widely available to women and some complained that even the information 
on the Internet was tilted towards negative experiences of breast reconstruction. 
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Despite having regrets about undergoing breast reconstruction, some women came to 
terms with their altered physical appearance.  When asked about her satisfaction with her breast 
reconstruction results, a white survivor (Age 42 at diagnosis; 2 children pre-diagnosis) 
exclaimed, “Well, I'm happy enough.  I came to the point where I thought my life, my boobs, 
and my life was so much more important than the other.”  In the grand scheme of their breast 
cancer journeys, the fact that they lived through it was most important.  Yet, breast surgery and 
reconstruction had a profound effect on these women’s self-image and there were racial 
discordances in how women coped with the realities of their altered bodies. 
 Discordances.  Although both survivors of color and white survivors expressed 
dissatisfaction with their breast reconstruction, there are differences in how they coped with 
their new bodies.  Both survivors of color and white survivors received follow-up surgeries to 
repair issues with their breast implants.  Yet, only one white survivor (Age 42 at diagnosis; 2 
children pre-diagnosis) went through multiple surgeries to achieve her ideal symmetrical 
breasts.  She was ultimately satisfied with her implants because she was able to regain breast 
sensation.  The plastic surgeon set low expectations for regaining breast sensation, so when it 
did return this made her more satisfied with her breast reconstruction results.  A survivor of 
color (Age 40 at diagnosis; 2 adopted children pre-diagnosis) who completed follow-up 
surgeries to fix issues with her implants drew the line with getting additional surgeries when her 
plastic surgeon suggested coming back for nipples: 
“After the last reconstruction, my doctor was like you know…you can come back and we 
can do nipples and blah, blah, blah.  I was like I do not care about nipples.  Do not talk to 
me about nipples; I will not be coming back for nipples.  [Laughs] And so you know of 
course it doesn’t look normal, but even with nipples it wouldn’t look normal to me 
because it’s so manmade you know.”   
 
Several women shared that they did not get nipples for similar reasons.  They did not want to 
endure the additional procedure that ultimately would not improve the appearance of their 
breast implants.  Some women struggled with their altered physical appearance.  Survivors of 
color complained the most about scarring and residual pain from stomach or back flaps used to 
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construct their new breasts.  In fact, survivors of color were the only ones to share that it was 
difficult for them to look at their undressed bodies in the mirror.  A survivor of color (Age 34 at 
diagnosis; 1 child pre-diagnosis) shared: 
“Nothing is ever like what God gave you.  Today I can say that I'm good and I'm happy 
with it, but initially, I mean it takes some getting used to.  Initially I would go in the 
bathroom and put the towel over the mirror into my shower and this is how I would do.  
Today I can say I'm good with them, I'm good without them.” 
 
She and other survivors struggled with body image issues due to the appearance of their breast 
implants.  Even though many of them reached a point of acceptance of their new physical 
appearance, it was evident that the implants could never replace the breasts they lost.   
Most of the women who had a mastectomy also received breast reconstruction.  
However, only a couple of white survivors shared that they did not undergo breast 
reconstruction.  When asked why she decided not to have breast reconstruction after her 
unilateral mastectomy, a white survivor (Age 40 at diagnosis; 2 children pre-diagnosis) stated:  
“I don’t want any more major surgeries that I don’t have to have.  I keep thinking 
someday there’s going to be an easier better solution as things progress.  Somebody the 
other day mentioned the 3D printing, you know how they’re printing like ears, and 
whatever, and they’re like why couldn’t they do that.  That’s what I’m going to wait for.  
You know somebody is going to print a breast.  Yeah I’m in no hurry.”   
 
After the completion of cancer treatment, undergoing an additional surgery deterred some 
women from enduring breast reconstruction.  Some of the women that did not receive breast 
reconstruction wore prostheses and others chose not to.  They seemed to be more comfortable 
with their altered physical appearance and like many of the women that received breast 
reconstruction or not, they realized their breasts did not define their womanhood. 
 
Theme 5: Menopause Symptoms Led to Sexual Health and Quality of Life Issues  
 Concordances.  A majority of the women experienced menopause symptoms induced 
by chemotherapy, adjuvant endocrine therapy, or post-cancer hysterectomies that affected their 
sexual health and quality of life.  The women discussed typical menopause symptoms, such as 
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hot flashes, vaginal dryness, low libido, and weight gain, while others suffered from less 
common side effects from chemotherapy and adjuvant endocrine therapy, such as neuropathy, 
vision impairment, and tear duct damage.  Some women welcomed the early onset of 
menopause and found ways to successfully manage the side effects.  A survivor of color (Age 45 
at diagnosis; 1 child pre-diagnosis) shared how she managed her menopause symptoms: 
“And you know people say it – women say you go through changes.  Yes, I had the hot 
flashes.  They weren't fun, but you learn to deal with them.  I found out exercising helped 
some.  And doing certain types of exercise, like yoga or breathing exercises – but it's just 
– you just have to be proactive and find these things and ask questions.  And eating.  You 
have to make sure you're eating – eating right.”   
 
Finding ways to manage symptoms made it easier for some women to embrace menopause.  
However, women with partners, especially those who had hormone receptor-positive tumors, 
found it challenging to find solutions for low libido and vaginal dryness.  Many of the over-the-
counter and prescription products available to combat vaginal dryness contain estrogen, which 
women with hormone receptor-positive tumors are discouraged from using.  Furthermore, they 
found it difficult to engage their providers in discussions about their sexual health and intimacy 
issues.  Even when they were able to have conversations with their providers, they did not 
receive adequate information to fully address their concerns.  When asked what reproductive 
health information she wished she had received prior to beginning treatment, a survivor of color 
(Age 40 at diagnosis; 2 adopted children pre-diagnosis) responded: 
“I guess more so on the effects of treatment on your actual sexuality and desires and 
what to do.  They kept telling me, ‘Well, there are things we can do.  There are things we 
can do.’  But I don't feel like I ever got much information on what those things were after 
the fact.  I have since gotten one – or tried one thing and it hasn't worked very well for 
me, so I just wish that all that had been given.”   
 
She and other survivors desired solutions to address their sexual health issues and they did not 
receive adequate medical counseling or support in this area.  Many of the women feared the 
challenges ahead with maintaining intimacy with their partners long-term since they 
experienced physical and emotional discomfort when engaging in sexual activity.  A white 
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survivor (Ages 28, 37, & 40 at diagnosis; 1 child pre-diagnosis and pregnant with 1 child at 
second diagnosis) shared:  
“So, I've had some problems with the dryness and, I guess, the lack of estrogen in my 
body – it's a problem. You know?  So, I do not have sex as much as I used to.  But I still 
do…  Thankfully, my fiancé’s very understanding about the whole thing.”   
 
Fortunately, many of the women had supportive partners that understood the toll that cancer 
treatment had taken on their bodies and how the nature of their sexual activity may be limited 
or changed due to the effects of menopause symptoms.  
 Discordances.  Although both survivors of color and white survivors experienced 
challenges managing the side effects of chemotherapy and adjuvant endocrine therapy, there 
were differences in their main complaints.  Survivors of color described their issues with 
excessive weight gain once they began adjuvant endocrine therapy and started experiencing 
menopause symptoms.  One survivor of color (Ages 29 & 37 at diagnosis; 4 children pre-
diagnosis) stopped taking a medication for menopause symptoms because she felt it was causing 
her weight gain.  She utilized non-pharmaceutical methods to manage her symptoms.  After her 
providers told her that there was nothing that could be done about her excess weight, another 
survivor of color (Age 40 at diagnosis; no children) accepted her 30-pound weight gain as a side 
effect of adjuvant endocrine therapy treatment and remained hopeful she would shed the extra 
weight once she stopped adjuvant endocrine therapy in the coming year.  While some survivors 
of color battled weight gain, a few white survivors discussed the unexpected side effects of 
adjuvant endocrine therapy.  Two white survivors participated in clinical trials where they 
consumed double doses of adjuvant endocrine therapy, such as Tamoxifen, for short bouts of 
time.  Both women reported developing a serious health issue that they felt resulted from this 
intensified adjuvant endocrine therapy.  These health issues included benign uterine/ovary 
growths and long-term tear duct impairment.  Other white survivors experienced neuropathy 
and vision impairment that may have been induced by chemotherapy and adjuvant endocrine 
therapy.  Beyond the sexual health-related issues that women experienced as a result of the early 
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onset of menopause, they also developed other long-term health challenges caused by their 
cancer treatment that affected their quality of life. 
 
Recommended Services and Resources for Premenopausal Breast Cancer Patients 
 In addition to exploring their breast cancer experiences and reproductive needs, we 
asked the women what types of information should young breast cancer patients receive about 
reproductive health and how should this information be delivered.  The women shared an array 
of interesting ideas that honed in on the need to develop and provide premenopausal breast 
cancer survivors with reproductive and sexual health information that addressed their specific 
needs and concerns. 
 The types of information that the women felt were necessary to deliver to young breast 
cancer patients included: 1) options and risks related to conceiving after treatment, including 
the cost of fertility preservation; 2) picture diary of the breast reconstruction process from 
mastectomy surgery through the post-reconstruction healing phase; 3) comprehensive 
information about the potential side effects of cancer treatments and medications; and 4) 
potential effect of cancer treatment on reproductive health and pregnancy outcomes.  
Furthermore, women with strong family histories of breast cancer felt medical providers should 
be more forthcoming about the increased risk of breast cancer associated with birth control use, 
so young women can make informed decisions about their contraception use.  In addition to 
more comprehensive reproductive health information, the women wanted providers to raise 
breast cancer patients’ awareness about the ability for them to conceive after treatment and 
genuinely support their patients’ decisions to pursue pregnancy.  They wanted to know the risks 
associated with bearing children after completing their treatment, but they also desired to be 
given the full spectrum of options for conceiving children and the possible pregnancy and birth 
outcomes (i.e., not just the potential negative outcomes). 
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 Along with advocating for typical avenues for educating patients, the women shared 
some innovative approaches for reaching young breast cancer patients.  They provided several 
recommendations for delivering reproductive health information.  First, all young breast cancer 
patients should receive one-on-one counseling with a navigator, peer mentor, or psychologist, so 
they receive the individualized emotional or reproductive health support they need.  Second, 
down time during appointments could be an opportune time to deliver reproductive health 
counseling and printed information (e.g., waiting room, while receiving chemotherapy).  Third, 
the cancer care providers could review key talking points or questions regarding reproductive 
health with patients (e.g., Are you experiencing any menopause symptoms that are causing 
discomfort?  If so, what are your concerns?), rather than asking more open-ended questions 
(e.g., Do you have any questions or concerns?).  Fourth, cancer centers should offer workshops, 
support groups, and other resources that are exclusively for young patients, who are at a 
different stage of life and have different needs than older patients.  Fifth, cancer centers should 
create a breast cancer information binder cover and materials that are more gender neutral 
since not all women connect to the pink-centric theme often associated with breast cancer 
paraphernalia.  Lastly, cancer centers should centralize and widely distribute information on 
workshops and resources, so this information reaches all patients.  Overall, the women felt that 
reproductive health information should be reiterated at various time points throughout breast 
cancer patients’ care.  They wanted the cancer center-based support to extend beyond the 
treatment period and be readily available to them during the survivorship period since they still 
manage the effects of cancer treatment on their health and quality of life for months to years 
after completing treatment. 
 
Discussion 
In an effort to learn more about the reproductive and sexual health needs of women with 
a breast cancer history, we interviewed women diagnosed at or before the age of 45 who did and 
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did not have children.  Through an examination of their expressed reproductive and sexual 
health needs and concerns around the time of their breast cancer diagnosis, we learned about 
the post-diagnosis birth status and racial concordances and discordances in these women’s 
experiences, as well as their recommendations for improving reproductive and sexual health 
counseling for young breast cancer patients.  We learned several things about women with a 
breast cancer history.  First, they are not receiving sufficient breast cancer treatment-related 
reproductive health information from their cancer care providers and are relying on the 
Internet, their OB/GYNs, and support groups to address their concerns since they found it 
difficult to discuss their reproductive and sexual health concerns with their male oncologists, in 
particular.  Second, they desire realistic expectations about their ability to conceive after 
treatment and for providers to support their decisions to become pregnant if they are healthy 
and able.  Third, breast cancer survivors and their younger family members are making 
treatment and lifestyle decisions based on their family history of breast cancer.  Fourth, some 
women have regrets about undergoing breast reconstruction and struggle with accepting their 
new bodies, but some have come to terms that their life is more important than their physical 
appearance.  Lastly, they learned to manage some treatment induced menopause symptoms, but 
are not receiving sufficient support in resolving their sexual health issues that have resulted 
from the early onset of menopause.   
Many of the women’s stories mirrored each other and attested to the spectrum of 
reproductive and sexual health needs and concerns that women with a breast cancer history 
have during the treatment phase and into survivorship.  Nonetheless, there were some 
discordances between women who did/desired and did not have a child after their breast cancer 
diagnosis, as well as between survivors of color and white survivors.  Women who had or still 
wanted children after completing treatment advocated for less invasive treatment options in 
order to preserve their fertility and leave the option open for them to attempt to conceive after 
treatment.  Compared to women who had completed their families prior to their diagnosis, the 
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women who wanted to conceive after treatment were more likely to receive information from 
their cancer care providers about fertility options, but this information mostly depicted the 
potential negative pregnancy and birth outcomes.  However, the women who desired to have 
children were the most remorseful about being unable to start or complete their families after 
completing breast cancer treatment.  Survivors of color were the only ones to report receiving 
ovary suppression shots to assist in the process of preserving their fertility during their breast 
cancer treatment.  They also shared more about their struggles with body image disturbance and 
how they had to work on acceptance of their physical appearance after treatment.  Unlike the 
white survivors, the survivors of colors discussed weight gain as a major adjuvant endocrine 
therapy or menopausal side effect.  The white survivors felt the information they received 
painted a bleak picture of their reproductive and sexual health outcomes, which was 
discouraging.  They were more likely to utilize cancer center-sponsored support groups and 
workshops, whereas the survivors of color were involved in community-based breast cancer 
support groups.  White survivors that had mothers who were also breast cancer survivors felt 
less terrified about the breast cancer journey and were more concerned about how their 
treatment decisions would affect their quality of life long-term.  Furthermore, they shared how 
younger generations in their families lived in fear of being diagnosed with breast cancer since 
their family history of it was so strong.  Only white survivors shared that they did not get breast 
reconstruction, participated in adjuvant endocrine therapy clinical trials, and experienced non-
reproductive health-related side effects of chemotherapy and adjuvant endocrine therapy that 
affected their quality of life (e.g., neuropathy, vision impairment, tear duct damage).  The 
experiences shared by these women with a breast cancer history were more similar than 
different, yet it is important to acknowledge how various sub-sets of women may have 
reproductive and sexual health needs and concerns that diverge from what is considered the 
norm. 
The literature examining the reproductive and sexual health needs of women with a 
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breast cancer history in the United Studies is limited, but has garnered more attention over the 
past few years.  Researchers have used validated survey instruments, focus groups, and in-depth 
interviews to determine what are the reproductive and sexual health needs of women with a 
breast cancer history.  Among the studies that have utilized qualitative research methods to 
learn about these issues from the perspective of breast cancer survivors there is a general 
consensus that premenopausal women are dissatisfied with the lack of information they are 
receiving about breast cancer treatment-related reproductive, fertility, and sexual health issues 
(30–34), which aligns with the findings of this study.  One study that explored how young breast 
cancer survivors’ values about conceiving after treatment influenced their treatment decisions 
compared the experiences of sub-groups of survivors (e.g., women who did versus did not have 
children after treatment), but they did not find any significant differences and only presented 
the joint findings.(32)  A majority of the women in these studies (81-100%) were white breast 
cancer survivors (30–33), except for one study that included only black women.(34)  The 
racially homogenous populations recruited for these studies did not allow for racial differences 
in experiences to be examined.  Lewis and colleagues (34) found that black women seemed to 
report more severe issues with their intimate relationships, distress with their fertility, and more 
often lacked information on sexual dysfunction after breast cancer compared to white women in 
other studies.  In contrast to Gorman et al.’s (32) finding that their participants (85% white) 
chose more aggressive treatment approaches since they were motivated by survival and 
preventing recurrence, our study found that women who desired to conceive after treatment 
were more likely to choose the least invasive treatment route, especially the survivors of color.  
Our findings mostly align with the previous literature and reinforce that young women with a 
breast cancer history are concerned about sexual dysfunction and body image (30); found it 
difficult to discuss reproductive and sexual health issues with their providers (17); felt that their 
cancer care providers were dismissive of or not knowledgeable about how to address their 
reproductive and sexual health concerns (31,33); and had to conduct their own research and 
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speak with other breast cancer survivors to learn more about breast cancer treatment-related 
reproductive health issues (32).  
The strengths of this study are grounded in the use of the Sort and Sift, Think and 
Shift© method, diversity of participants, and engagement of breast cancer survivors and 
advocates throughout the study.  The method used to review and analyze the interview data 
allowed for the findings to be grounded in the true experiences of the women interviewed and 
not limited to our preconceived notions.  This iterative review and analysis process of the 
interview data paved the way for sharing findings that truly reflect the participants’ experiences.  
Additionally, we recruited a diverse group of women with a breast cancer history, so that 
comparisons could be made based on post-diagnosis birth status and race.  Our engagement of 
breast cancer survivors and advocates in various aspects of the study, including the development 
of recruitment materials and the interview guide, as well as feedback on the themes and 
illustrative quotes prior to the dissemination of the findings, further strengthened our findings.  
Overall, we placed value in the experiences of women with a breast cancer history and attempted 
to incorporate their voices and insights in various aspects of the study’s process in order to 
enhance the validity of our findings. 
The main limitations of this work pertain to the recruitment sources and the 
generalizability of the findings.  We recruited a majority of the women via cancer center-
supported and community-based breast cancer support groups located in a major metropolitan 
area in North Carolina and most of these women received care from the same regional cancer 
center.  The resources available at this one regional facility may vary from other cancer centers 
in North Carolina.  This may explain some of the differences in participants’ access to cancer 
center-sponsored workshops that covered reproductive and sexual health topics.  The 
experiences of the women interviewed did partly depend on the providers and resources 
available to them at their given cancer centers.  Recruiting women from a range of cancer 
centers in North Carolina may have increased the diversity of women we interviewed.  
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Furthermore, since this study is based in North Carolina and includes women with convenient 
access to a cancer center, this study may not be generalizable to women in other parts of the 
United States, especially women with less access to medical facilities.  Future studies on this 
topic would benefit from recruiting from a range of cancer centers and within rural 
communities.  Despite these limitations, this study provides a strong methodology that can be 
replicated and a basis for comparison with a more diverse recruitment sample. 
It is apparent from this study’s findings that women with a breast cancer history are in 
need of and desire more education and resources to address their reproductive and sexual 
health concerns.  Young breast cancer survivors would greatly benefit from receiving 
reproductive health counseling and access to resources to address their concerns during the 
breast cancer treatment phase and beyond.  Additional resources outside of the services 
currently offered by cancer care providers are needed.  Offering regularly scheduled workshops 
in the cancer center that cover reproductive and sexual health topics, as well as having 
designated reproductive health specialists available may be useful resources and safe spaces for 
women, especially those who are not comfortable discussing such topics with their cancer care 
providers.  Additionally, providing trustworthy websites that discuss and provide solutions for 
breast cancer patients’ reproductive health concerns may be another welcomed resource.  It may 
also be beneficial for cancer centers within larger healthcare systems to partner with their 
obstetrics and gynecology departments to develop useful approaches for jointly supporting 
breast cancer patients with reproductive health concerns or that desire to conceive after the 
completion of their treatment.  Overall, the reproductive health needs and concerns of young 
breast cancer survivors deserve more attention as an important quality of life and survivorship 
issue. 
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TABLES 
TABLE 3.1. CHARACTERISTICS OF 17 YOUNG WOMEN WITH A BREAST CANCER HISTORY AT TIME OF 
INTERVIEW 
  N or Mean (SD) 
Education   
Some or graduated college (13-16 years)  10 
Professional/graduate degree (≥17 years)  7 
Marital Status   
Married/Engaged  13 
Divorced  3 
Single/Never Married  1 
Parity   
Nulliparous (0 births)  2 
Primiparous (1 birth)  4 
Multiparous (≥ 2 births)  11 
Birth of Child(ren) Relative to Breast 
Cancer Diagnosis Date 
  
No births  2 
Birth(s) occurred before diagnosis  12 
Birth(s) occurred after diagnosis  1 
Birth(s) occurred before and after diagnosis  2 
Race/Ethnicity   
White, non-Hispanic  10 
Black, non-Hispanic  5 
Other  2 
Smoking   
Never Smoked  14 
Former Smoker  3 
Stagea   
Stage 0 (In Situ)  2 
Stage 1  4 
Stage 2  7 
Stage 3  3 
Unsure  1 
Hormone Receptor Statusa   
ER+/PR+  9 
ER+/PR-  4 
ER-/PR-  1 
ER-/PR-/HER2- (Triple Negative)  3 
Treatment Typea,b   
Lumpectomy  12 
Unilateral Mastectomy  3 
Bilateral Mastectomy  4 
Chemotherapy  11 
Radiation  12 
Breast Reconstruction  5 
Adjuvant Endocrine Therapy  14 
Breast Cancer Recurrence   
1 breast cancer diagnosis  15 
2 or more breast cancer diagnoses  2 
BRCA Mutation   
No  12 
Yes  1 
Variants of Unknown Significance  1 
Not Tested  3 
Time Since Diagnosisa   
 < 1 year  2 
1 ≤ years < 5  6 
5 ≤ years < 10  4 
≥ 10 years  5 
Age at Diagnosis (in years)a  38.6 (5.0) 
Range  28-45 
Age at Time of Interview (in years)  45.8 (7.2) 
Range  37-64 
N=total number; SD= standard deviation 
aRefers to participant’s first breast cancer diagnosis 
bThis column does not add up to 100% since a participant may be included in >1 category based on their treatment regimen 
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TABLE 3.2. FIVE OVERARCHING THEMES AND SELECTED ILLUSTRATIVE QUOTES REGARDING THE 
REPRODUCTIVE AND SEXUAL HEALTH NEEDS IDENTIFIED BY WOMEN WITH A BREAST 
CANCER HISTORY 
1: Received Limited Reproductive Health Information 
“No, the only thing he said was just don't get pregnant right now.” 
 
“There wasn’t just a ton of resources around reproductive or – reproductive health in general, either on 
the fertility side or the sexual functioning side.  It was just not there.  So, I did a lot of my own research…  
But going on the Internet helped me get a more balanced picture from different resources of what I 
might be looking at.  But you – yes, chemopause is a thing that happens.  Maybe that will happen, 
maybe it won't.  There's really no way to predict.  You know?  More of the spectrum of that experience 
rather than, ‘Here's all the awful things that are probably gonna happen to you, so get ready.’” 
 
“It was only discussions at group about people that had concerns with intimacy or side effects of some of 
the drugs.  Nothing specific was given to me.  I just had exposure from the women around me, not from 
a doctor or a nurse.” 
 
“…my oncologist…he's great.  He actually draws pictures and writes everything down so you have 
something to take away.  It's really a wonderful approach.  But he's listing side effects and he's like, 
‘Hair loss and nausea, but here's what we're gonna do.’  And I had to actually ask, ‘Is this gonna kick 
me into menopause?’ …just wasn't even brought up as a concern, like it was not as important.  But I 
was super concerned about it.  Anything that I've learned about what kind of impact is this going to 
have reproductively or sexually has just been independent study. …And I just felt like there wasn't 
good information about that.  It's hard to get the doctor to talk about it.” 
 
2: Desired Realistic Expectations of Conceiving Post-Treatment 
 “I wanted to preserve that option because even though I recognize with my age that it presents some 
health risk for my age…  And it has been posed to me to look into adoption, but I won't say it hasn't 
crossed my mind, but that's not my desire right now.  I wanted to at least leave the possibility open to 
preserve that, so that's my right to choose whether or not to do that.” 
 
“I was surprised, actually, how easy I conceived our daughter.  'Cause I was – I don't know, I just think 
that – You know, I wasn’t very young; I was 38.  I just thought it was gonna take – it's going to take a 
while.  But I think – yeah, I think we – I got pregnant after a couple of months.” 
 
“Because of my age, cancer, and then right away, like as soon as I found out I was pregnant I went to 
the doctor…  The lady said to me…, ‘The chances of this being successful for you and the baby are very 
small.’  She was just like, ‘By 32 weeks, I expect to have you induced, in the hospital, and having a 
premature baby.’ …And so I left that doctor's office just pure crying my eyes out.  I went home, I told my 
husband…, ‘I'm just not going to be able to carry this baby.  She's going to die.  She's going to come out 
sick.’  And I made it 39 weeks.  Absolutely healthy.” 
 
3: Family History of Breast Cancer Influenced Lifestyle Choices 
“And I think for me, I was not totally shocked to be diagnosed, 'cause my mother was diagnosed at a 
relatively young age, and I watched my mother go through treatment.  So, I think I had sort of an 
innate sense that you can come through this and come out okay, 'cause she's now 60-whatever-she –
is.  You know?  And she's happy, and she dates, and she has a – she's a registered dietitian, and… 
She's totally fine.  So, I had a very clear role model of, ‘You can come through this,’ and it will be 
terrible' 'cause it was, ‘and still have a great life on the other side of it.’  So, I think I was more 
concerned about not, ‘Am I gonna die,’ but, ‘What is the quality of life that I'm gonna experience, and 
what does that look like?’  So, I wonder if that makes me a bit of an outlier.  I didn't have the same 
sort of cancer terror that I think some people will have.” 
 
“I've got a few nieces that have told me that [they are] exercising and running half marathons and 
doing things that me and my sisters, none of us are exercise anything…  I feel like I'm active, but I 
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don't do structured exercise.  And my sisters are the same way, but some of our nieces are not doing 
that at all.  They're Fitbit wearers… and part of the reason they do that is because they're worried.  
…So, they have made some lifestyle decisions.  …like it's hardwired in [them], ‘What can we do to 
make ourselves healthier by what we eat?’…And I think it is partially because of the cancer stuff in 
our family.” 
 
4: Struggled with Adapting to Altered Physical Appearance 
“I think just the scars and the implant process.  It doesn't feel – you don't feel like yourself there after 
the implants.  You know.  And especially during the expander part, it feels very foreign and they're 
very hard.  And every time you breathe, it's a reminder that there's something fake going like this 
every time you breathe.  And then they put the implants in, and it's much better, but it still doesn't 
feel like you used to.” 
 
“Sometimes I say if I could go back and change some things about my journey, that may have been one 
of the things that I would've done, is just kind of let it be.  Um-mm. you know, because there's so many 
prosthesis and apparatuses and you know.  Just like you can't look at me today and tell, I don't think 
anybody would've been able to look at me and tell otherwise either.” 
 
“Nothing is ever like what God gave you.  Today I can say that I'm good and I'm happy with it, but 
initially, I mean it takes some getting used to.  Initially I would go in the bathroom and put the towel 
over the mirror into my shower and this is how I would do.  Today I can say I'm good with them, I'm 
good without them.” 
 
5: Menopause Symptoms Led to Sexual Health and Quality of Life Issues  
“I guess more so on the effects of treatment on your actual sexuality and desires and what to do.  They 
kept telling me, ‘Well, there are things we can do.  There are things we can do.’  But I don't feel like I ever 
got much information on what those things were after the fact.  I have since gotten one – or tried one 
thing and it hasn't worked very well for me, so I just wish that all that had been given.” 
 
“So, I've had some problems with the dryness and, I guess, the lack of estrogen in my body – it's a 
problem. You know?  So, I do not have sex as much as I used to.  But I still do…  Thankfully, my fiancé’s 
very understanding about the whole thing.”  
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CHAPTER 4: CONCLUSIONS 
Overview of Findings 
 This mixed methods analysis provided additional insights on the risk of adverse birth 
outcomes and reproductive health concerns of premenopausal breast cancer survivors in the 
United States.  The quantitative findings exhibited that premenopausal breast cancer survivors 
have a higher prevalence of preterm birth and low birthweight, especially if they received 
chemotherapy treatment or conceived less than two years after their diagnosis date.  
Furthermore, there seems to be a significant interaction between breast cancer and 
race/ethnicity in terms of the prevalence of preterm birth, but this interaction is not significant 
for low birthweight.  The qualitative findings demonstrated that women with a breast cancer 
history are in need of reproductive and sexual health resources to address their spectrum of 
concerns.  Their cancer care providers are not providing sufficient reproductive health 
counseling prior to treatment and during their breast cancer journeys, so women have been 
utilizing books and support groups, as well as consulting their gynecologists to address their 
concerns.  Although many of the women shared similar stories, there were differences in 
experiences according to post-diagnosis birth status and race.  These discordances included the 
findings that women wanting to conceive post-treatment were more likely to seek less invasive 
treatment options, survivors of color shared more about their challenges with body image 
disturbance and weight gain, and white survivors were more likely to use cancer center-
sponsored support groups and workshops.   
Overall, the quantitative findings demonstrated women with a breast cancer history have 
an increased preterm birth and low birthweight risk.  The qualitative findings complement the 
quantitative findings by showing the importance of providing young breast cancer patients with 
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reproductive health counseling, so they are aware of the adverse pregnancy outcome risks 
associated with their course of cancer treatment.  The importance of reproductive health 
education for breast cancer providers and their patients resonated with the findings from both 
aims of this study.  Yet, these findings should be interpreted with caution since cancer treatment 
and the population demographics of North Carolina have changed over the 20-year period of 
this study.  From 1990 to 2009, chemotherapy and adjuvant endocrine therapy have 
significantly advanced, more women are delaying childbearing and having their first birth in 
their thirties and even forties, and more women are not married at the time they give birth.  
Since the quantitative study factored in cancer treatment and maternal characteristics in its 
analyses, such as chemotherapy, maternal age, and marriage the findings reported may be 
influenced by a cohort effect.  This means findings from women in the first decade of this study 
could have different results from those in the second decade.  Nonetheless, the use of methods 
triangulation in this study provided a more complex and holistic look into the reproductive 
health outcomes and needs of women with a premenopausal breast cancer history. 
 
Concordance between the Findings, Guiding Frameworks, and Conceptual Model 
 The healthy mother effect bias theory (1–3), Lu’s and Halfon’s (4) life-course health 
development model, as well the biological effect of chemotherapy on reproductive function are 
the frameworks that guided this study.  From these guiding theories, a conceptual model was 
developed to depict how cumulative life exposures (i.e., risk and protective factors) may 
influence the reproductive health trajectories of premenopausal breast cancer survivors, as well 
as the assumed discordance in the trajectories of black and white women.  The findings from 
this study confirmed some aspects of the conceptual model and provided a different perspective 
on how cumulative exposures may contribute differently to the risk of adverse birth outcomes 
among black premenopausal breast cancer survivors compared to their white counterparts. 
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 Healthy mother effect bias and the biological effect of chemotherapy on reproductive 
function were evident in the quantitative and qualitative findings.  The quantitative findings 
showed that having a breast cancer history does increase a woman’s risk of experiencing an 
adverse birth outcome, but receiving chemotherapy and having a child within two years of being 
diagnosed amplified this risk.  Breast cancer patients who do not undergo chemotherapy are 
more likely to have in situ breast cancer or stage 1 breast cancer tumors that are hormone 
receptor-negative or less than one centimeter in size.(5)  Not receiving chemotherapy may 
indicate that the patient has a less invasive form of breast cancer and it also means the patient 
was not exposed to the known toxic effects of this treatment on reproductive function.(6–9)  
Furthermore, women that postponed pregnancy for at least two years after their diagnosis date, 
had more favorable birth outcomes.  Therefore, women that do not undergo chemotherapy or 
wait more than two year post-diagnosis may be more “healthy” and able to conceive post-
treatment.   
Healthy mother effect bias was present in the qualitative findings, but in a different way 
than the quantitative findings.  Three of the women with a premenopausal breast cancer history 
that were interviewed had children after their breast cancer diagnosis.  All of these women had 
triple negative breast cancer and received chemotherapy, but did not receive endocrine therapy.  
Since they did not have to take endocrine therapy for five to ten years after their treatment 
regimen was completed, they were able to become pregnant naturally and delivered healthy 
infants despite having received chemotherapy treatment.  These women with a breast cancer 
history were able to successfully conceive and they may have been “healthy” enough to do so 
because they did not have to go through endocrine therapy, which may have caused age-related 
decline in fertility.(6)  They were able to optimize their remaining reproductive years and 
premenopausal status to conceive post-treatment and reach their ideal family size goals.  The 
findings from this mixed methods study suggest that less aggressive treatment regimens and 
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postponing pregnancy for at least two years may decrease young breast cancer survivors’ risk of 
adverse birth outcomes. 
 The original depiction of the biological effect of chemotherapy on reproductive function 
in this study’s conceptual model has shifted as a result of the findings.  At the onset of this study, 
it was believed that the reproductive function and potential of black women with a breast cancer 
history would decrease at a higher rate than their white counterparts at the point chemotherapy 
is received.  The quantitative study revealed that although both black and white breast cancer 
survivors had a higher prevalence of preterm birth and low birthweight compared to the general 
population and their racial counterparts without a breast cancer history, the white breast cancer 
survivors exhibited higher preterm birth prevalence ratios than the black breast cancer survivors 
in the stratified (Table 2.4) and joint effects (Table 2.5) models.  Due to black breast cancer 
survivors’ lifetime cumulative exposure to potentially more risk factors than protective factors 
and baseline risk for preterm birth and low birthweight, this risk was not exacerbated by the 
additional assault of breast cancer treatment on their reproductive function.  Their risk of 
adverse birth outcomes was essentially unchanged by being diagnosed with breast cancer.  For 
example, in the joint effects models (Table 2.5), compared to white women in the general 
population, the black women in the general population exhibited a 45% increase in preterm 
birth risk and black breast cancer survivors had a 90% increase in risk, yet the 95% confidence 
intervals for these groups’ prevalence ratios overlapped greatly (e.g., 1.44-1.47 and 1.45-2.50, 
respectively).  This indicates that these two point estimates are more similar than different; 
therefore, there may not a significant difference in preterm birth risk between black survivors 
and their racial counterparts in the general population.  Breast cancer treatment did appear to 
greatly affect the reproductive function of white breast cancer survivors.  Although it was 
assumed that white survivors have more cumulative exposures to protective factors than risk 
factors over their lifetimes, their risk of preterm birth appeared to be higher than what was 
indicated for black survivors.  White breast cancer survivors had more than two times the 
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preterm risk of white women without a breast cancer history, whereas black breast survivors had 
a 90% increase in risk compared to the same population.   
Since nationwide black women have higher rates of preterm birth than white women 
(10), at the onset of this study it was assumed that black survivors would also have a higher 
prevalence of preterm birth compared to white survivors, yet this was not the case.  To highlight 
these new insights on the biological effect of chemotherapy on reproductive function, the 
conceptual model was updated to exhibit that black survivors who receive chemotherapy do not 
experience the severity of effect on their reproductive potential as predicted and white survivors 
who undergo chemotherapy actually experience a greater detriment to their reproductive 
potential than black survivors (Figure 4.1).  Yet, the disparity in reproductive potential between 
black and white breast cancer survivors continues to exist.  The gap may not be as wide as 
predicted, but these results attest to the need for all premenopausal breast cancer survivors to 
receive reproductive health counseling prior to, during, and after the completion of treatment. 
 
Practice and Research Implications 
 A breast cancer diagnosis and its treatment have long-term implications on the health 
and quality of life of women.  Understanding the effects of breast cancer diagnosis and 
treatment on future reproductive and sexual health outcomes is an important concern for 
premenopausal women diagnosed with breast cancer.  Women with a breast cancer history may 
benefit from targeted preconception health services and reproductive health counseling prior to 
and after cancer treatment.  Cancer care providers should be equipped to educate breast cancer 
patients about the potential harmful effects of cancer treatment and the range of potential 
pregnancy and birth outcomes.  Yet, if they are not able to provide this education, they should be 
able to refer their patients to a knowledgeable and easily accessible resource.  Nonetheless, 
additional resources outside of the services currently offered by cancer care providers are 
needed.  Offering regularly scheduled workshops that cover reproductive and sexual health 
 91 
topics, as well as having designated reproductive health specialists available in the cancer center 
may be useful resources and safe spaces for women, especially those who are not comfortable 
discussing such topics with their cancer care providers.  It may also be beneficial for cancer 
centers within larger healthcare systems to partner with their obstetrics and gynecology 
departments to develop useful methods for jointly supporting breast cancer patients with 
reproductive health concerns or that desire to conceive after the completion of their treatment.  
Overall, the reproductive health needs and concerns of young breast cancer survivors deserve 
more attention as an important quality of life and survivorship issue.     
Mixed methods studies may be a beneficial avenue for further exploring the birth 
outcomes and reproductive needs of premenopausal breast cancer survivors.  Longitudinal 
studies that follow premenopausal breast cancer patients from diagnosis through treatment 
completion to a post-treatment pregnancy or birth would provide additional insight into the 
reproductive health issues that these women endure and their range of pregnancy outcomes.  A 
qualitative research component should be conducted concurrently with a longitudinal 
quantitative study.  The qualitative study has the ability to reveal a deeper understanding of 
premenopausal breast cancer survivors’ decision-making process regarding their treatment 
regimen as it relates to their post-treatment childbearing goals and the influence their cancer 
care providers may have on their treatment choices.  They can also shed light on how their 
reproductive health, sexual health, and pregnancy outcomes influence their quality of life as 
breast cancer survivors.  The triangulation of these two methods may provide a more 
comprehensive view of the reproductive health experiences and needs of young breast cancer 
survivors than a quantitative or qualitative study alone. 
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FIGURES 
Figure 4.1. Revised conceptual model of how risk factors and protective factors differentially 
influence the reproductive potential of black and white women with a 
premenopausal breast cancer history 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This model is adapted from Lu’s and Halfon’s life-course health development model 
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APPENDIX 1: BORN STUDY IN-DEPTH INTERVIEW GUIDE 
1ST INTERVIEW 
 
Thank you (participant #_____) for agreeing to participate in this interview today the 
(day_____) of (month_____) (year_____).  During this first interview, I am going to 
ask you questions about your reproductive history, breast cancer diagnosis and treatment, 
and overall experience through the treatment process, as well as your reproductive health 
experiences around the time you were diagnosed with breast cancer.  As I’ve shared with you 
before when we went through the consent form, I will be asking questions that may be 
sensitive topics for you.  If you are not comfortable answering a question, please let me know 
and we can skip it.  Do you have any questions before I begin?  (PAUSE; ADDRESS ANY 
QUESTIONS)  Okay, let’s begin!   
 
I’m going to start off by asking you some questions about your reproductive history.  Some of 
these questions may be sensitive, so please feel free to let me know if you want to skip a 
question.  That’s perfectly okay. 
 
SECTION 1: REPRODUCTIVE HISTORY 
(1.1) How many times have you been pregnant? 
(If 0, then SKIP to Section 2) 
 
(1.2) How many times have you given birth?  
(1.3) How many living children do you have?  
   
  CHILD 
#1 
CHILD 
#2 
CHILD 
#3 
CHILD 
#4 
CHILD 
#5 
(1.4) What is child _’s 
birthdate? (mm/dd/yyyy) 
     
(1.5) What was his/hers 
birthweight? (grams or 
lbs/oz) 
     
(1.6) How many weeks 
pregnant were you when 
you had child _? 
     
(1.7) Did child _ have any 
congenital abnormalities? 
     
(1.8) Did you have any 
complications that 
developed during this 
pregnancy? (e.g., 
preeclampsia, gestational 
diabetes, high blood 
pressure, preterm 
contractions, placenta 
previa) 
     
(1.9) Did you breastfeed child 
_?  If so, for how long?  
What are some notable 
challenges or successes 
you had when 
breastfeeding? 
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In this next set of questions, I’m going to ask you questions about your breast cancer journey, 
including your diagnosis and treatment.  
 
SECTION 2: BREAST CANCER DIAGNOSIS and TREATMENT  
(2.1) Please share with me your breast cancer diagnosis story. 
 How old were you when you were diagnosed with breast cancer? 
 
 What stage of breast cancer did you have at the time you were diagnosed? 
 
(2.2) For your first breast cancer diagnosis, do you know the details of the type of breast 
cancer you had?  If so, what are the markers or sub-types of breast cancer that you had? 
 
LIST OF EXAMPLES 
 MARKERS: ER, PR, and HER2 +/-  
 
 PATHOLOGY SUB-TYPES: Luminal A/B, triple-negative, basal-like tumors, 
HER2 type, normal breast like 
 
 HISTOLOGY: in-situ (ductal or lobular), invasive 
 
(2.3) Have you ever been tested for the BRCA 1 or 2 gene mutation?   
 Do you have either of these gene mutations?  If so, which one? 
 
(2.4) What is your family history with breast cancer?   
 Which members of your family have been diagnosed with breast cancer?   
 
 Was your family member(s) under the age of 50 OR 50 years old or older at the 
time s/he was diagnosed with breast cancer? 
 
(2.5) Tell me about what type(s) of breast cancer treatment you received. 
 What type of surgery did you receive (e.g., lumpectomy, partial or total 
mastectomy)? 
 
 If you had chemotherapy, how many sessions did you receive?  For how long? 
 
 If you had radiation, how many sessions did you receive?  For how long? 
 
 If you had hormonal therapy, what type did you receive?  For how long? 
o Drug (Brand Name): Tamoxifen (Nolvadex)*, Goserelin (Zoladex)*, 
Leuprolide (Lupron)*, Anastrozole (Arimidex), Letrozole (Femara), 
Exemestane (Aromasin) 
o * = Used in pre-menopausal women 
 
(2.6) What was your experience with breast reconstruction? 
 
(2.7) Have you been diagnosed with any other cancers before?  If so, which types of cancer?  
When were you diagnosed with these cancers (e.g., month/year, age)? 
 Have you had any recurrences of breast cancer?  If so, which types of cancer?   
When did these cancer reoccurrences take place? 
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Now, I’m going to ask you some questions about your reproductive health experiences around 
the time you were diagnosed with breast cancer. 
 
SECTION 3: REPRODUCTIVE HEALTH CONCERNS around  
BREAST CANCER PERIOD 
(3.1) What was your ideal family size prior to being diagnosed with breast cancer? 
 Had you completed your family at the time you were diagnosed?   
 
 If not, how many more children did you want? 
 
(3.2) What was your relationship status at the time of your breast cancer diagnosis?   
 Were you single, in a relationship, or married? 
 
(3.3) When you were diagnosed with breast cancer, did you have any concerns about how the 
treatments may impact your reproductive health, such as the onset of menopause, 
fertility capability, sexual activity, reproductive outcomes, etc.?  
 If YES: What were your concerns? 
o How were these concerns raised with your doctors, if at all? 
o If you did, how did your doctors react to your concerns? 
o How helpful were your doctors with addressing your concerns, or not? 
 
 If NO: Why didn’t you have any concerns? 
 
(3.4) Did being diagnosed with breast cancer influence your ideal family size goals?  Will you 
please tell me more about that? 
 
(3.5) If you had children after your diagnosis, did being a breast cancer survivor influence 
your ability or desire to breastfeed your child(ren)? 
 If YES: How did you cope with that? 
 
(3.6) Have you had any previous surgeries on your uterus, fallopian tubes, or ovaries?   
 If so, why did you have this surgery? 
 Did this surgery take place before of after your breast cancer treatment? 
 
 
I just have two more general questions to ask you and then we’ll be done for today. 
 
SECTION A: MISCELLANEOUS QUESTIONS 
(A.1) Is there any additional information that I did not cover that you would like to share 
with me? 
 
(A.2) Do you have any questions for me? 
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Thank you for meeting with me today!  I really appreciate you participating in this interview 
and for thoughtfully responding to all of my questions.  Your responses will truly help me learn 
more about the experiences of young breast cancer survivors.  Here’s $25 cash as a token of 
my appreciation for you spending time with me today.   
 
I’d like to schedule a time to conduct the second interview with you.  When’s a good day and 
time for us to meet up again?   
 
(2nd Interview Date/Time ________________________________________) 
 
I’ll give you a call and send you an email at least 2 days before the next interview.  If you have 
any questions in the meantime, feel free email or call me at the contact information listed on 
the consent form.  Thank you again for everything!   
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2nd INTERVIEW 
 
Thank you (participant #_____) for agreeing to meet with me for a second time and 
participating in this interview today the (day_____) of (month_____) (year_____).  
During this second interview, I am going to ask about reproductive health information you 
may or may not have received, any reproductive or fertility issues that occurred during or 
after your breast cancer treatment, and life experiences that may have impacted your health.  
 
 As I shared with you during the last interview, I will be asking questions that may be sensitive 
topics for you.  If you are not comfortable answering a question, please let me know and we 
can skip it.  Do you have any questions before I begin?  (PAUSE; ADDRESS ANY 
QUESTIONS)  Okay, let’s begin!   
 
Now, I’m going to ask you about the information you may have received about your 
reproductive health around the time of your breast cancer diagnosis and treatment. 
 
SECTION 4: REPRODUCTIVE HEALTH INFO RECEIVED 
(4.1) What types of information did you receive on the impact of cancer treatment on your 
reproductive health?  (If the answer is NONE, then SKIP to question 5.1) 
 Who gave you this information?  
 
 At what point during your care was this information given to you (e.g., prior to, 
during, or after treatment completed)? 
 
 Did you ask for this info, was it just given to you, or did you find it on your own?   
 
 How useful was the information you received? 
 
 What kind of reproductive health or fertility counseling did you receive?   
 
(4.2) Out of all the resources you received to address your questions and concerns, which was 
your favorite resource?   
 
(4.3) What is your opinion of the information you received about the impact of cancer 
treatment on your reproductive health?   
 Did you receive enough information to address your concerns? 
 
(4.4) From the information you received, what did you learn about the potential impact of 
cancer treatment on your reproductive health?   
 How did this information influence your decisions about your family completion 
goals? 
 
(4.5) What reproductive health information do you wish you had received before you began 
treatment? 
 
 
Now, I’m going to ask you some more sensitive questions about your reproductive health.  
Please let me know if there is a question that you don’t want to answer and we can definitely 
skip it. 
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SECTION 5: REPRODUCTIVE/FERTILITY ISSUES 
(5.1) What types of menstrual cycle related issues have you experienced over your lifetime 
(e.g., irregular menses, absence of menses, onset of menopause)?  
 If so, at what age did this take place?   
 
 How long did this issue last?   
 
 How was your menstrual cycle different after you received and completed your 
breast cancer treatment compared to before you were diagnosed with cancer? 
 
 Did you ever regain your menses while you were still being treated? 
 
(5.2) After you completed your treatment, what were your plans for starting/completing your 
family?  
 Why did or didn’t you want to have children after completing your treatment? 
 
 What type(s) of contraception did you use? 
 
(If the answer was they DID NOT want any children, then SKIP to Section 
6)   
 
(5.3) What was your experience with trying to conceive children after completing your 
treatment? 
 Were there any setbacks or difficulties you experienced with getting pregnant? 
 
(5.4) Did you have any fertility treatments prior to beginning your breast cancer treatment?   
 If so, what type? 
 
 What information were you provided about these methods from your cancer care 
team? 
 
 What information did you discover on your own? 
 
(5.5) Did you utilize any assisted reproductive technologies (ARTs) to help you become 
pregnant after you completed your treatment?   
 If so, what type? 
 
 Did you become pregnant after using the ARTs? 
 
 What information were you provided about these methods from your cancer care 
team? 
 
 What information did you discover on your own? 
 
 
 
This next section of questions will allow me to learn more about how historical and social 
factors may have impacted your health.  This will include questions about your cancer care 
team and race.  If you feel uncomfortable with responding to any of the questions, please let 
me know and we can skip those questions. 
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SECTION 6: SOCIAL DETERMINANTS OF HEALTH 
(6.1) How was your overall experience with receiving care at your cancer center? 
 Did you have any barriers or challenges to receiving care? 
 
 Do you feel you were treated differently than other patients during your care?  
 
 If so, why do you have the sense that your experience was different than other 
patients? 
 
(6.2) I’m going to ask you a few questions about the race/ethnicity and gender of the 
members of your cancer care team.  Some patients like to receive care from doctors that 
look like them, so I want to learn more about how this may have impacted your care 
experience, if at all.   
 
What race and gender is your surgeon?  How about your medical oncologist?  How 
about your radiation oncologist? 
 How did the race or gender of your cancer care team members positively or 
negatively impact your care experience, if at all? 
 
(6.3) What types of challenges did you face while going through your cancer journey? 
 Were there any challenges at home? 
 
 Were there any challenges at work? 
 
 Were there any challenges in your community (e.g., church, neighborhood, social 
network, etc.)? 
 
 Were there any challenges at your cancer center or hospital? 
 
(6.4) What types of challenges did you face while trying to become pregnant after your breast 
cancer treatment? 
 Were there any challenges at home? 
 
 Were there any challenges at work? 
 
 Were there any challenges in your community (e.g., church, neighborhood, social 
network, etc.)? 
 
 Were there any challenges at your cancer center or hospital? 
 
(6.5) How can cancer centers and the medical system help young breast cancer survivors 
overcome barriers to becoming pregnant after treatment? 
 
 
I just have four more general questions to ask you and then we’ll be done for today. 
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SECTION B: MISCELLANEOUS QUESTIONS 
(B.1) How should information regarding the impact of breast cancer treatment on 
reproductive health during and after treatment be delivered to young breast cancer 
survivors’? 
 EXAMPLES of methods for delivering information: brochures, Internet links, 
videos, 1-on-1 counseling (with doctor, nurse, navigator, health educator), 
group counseling 
 
(B.2) What types of information should young breast cancer survivors receive about their 
reproductive health during and after treatment? 
 
(B.3) Is there any additional information that I did not cover that you would like to share 
with me? 
 
(B.4) Do you have any questions for me? 
 
 
Thank you for meeting with me today!  I really appreciate you participating in this interview 
and for thoughtfully responding to all of my questions.  Your responses will truly help me learn 
more about the reproductive health experiences of young breast cancer survivors.  Here’s $35 
cash as a token of my appreciation for you spending time with me today.   
 
After I finish conducting interviews and analyze all of the transcriptions of these interviews, I 
plan to organize a session where I will invite all of the women I interviewed and I will share 
my findings to receive additional feedback and insights.  Are you interested in me contacting 
you about this session? (☐  YES ☐  NO)  Is it best to email or call you?  (☐  EMAIL ☐  CALL) 
 
Thank you again for everything! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
APPENDIX 2: CHARACTERISTICS OF LIVE BIRTHS ACCORDING TO MOTHER’S 
RACE/ETHNICITY, NORTH CAROLINA 1990-2009 
 
  White, Non-
Hispanic 
(N=1,383,302) 
Black, Non-
Hispanic 
(N=528,967) 
Breast Cancer History  N % N % 
No  1,382,978 99.98 528,779 99.96 
Yes  324 0.02 188 0.04 
Preterm Birth  0 0.0 0 0.0 
Term (≥37 weeks gestation)  1,251,260 90.5 452,620 85.6 
Preterm (<37 weeks gestation)  130,808 9.5 75,326 14.2 
Missing  1,234 0.1 1,021 0.2 
Low Birthweight      
Healthy weight (≥2,500 grams)  1,285,994 93.0 457,767 86.5 
Low birthweight (<2,500 grams)  97,308 7.0 71,200 13.5 
Missing  0 0.0 0 0.0 
Education      
Less than high school (≤11 years)   168,189 12.2 98,010 18.5 
High school diploma (12 years)  431,416 31.2 231,676 43.8 
Some or graduated college (13-16 years)  636,465 46.0 178,660 33.8 
Professional/graduate degree (≥17 years)  145,160 10.5 19,591 3.7 
Missing  2,072 0.2 1,030 0.2 
Marital Status      
Married  1,134,949 82.1 186,223 35.2 
Not married  248,036 17.9 342,631 64.8 
Missing  317 0.02 113 0.02 
Parity      
Primiparous (1 birth)  599,342 43.3 188,072 35.6 
Multiparous (≥ 2 births)  783,960 56.7 340,895 64.5 
Missing  0 0.0 0 0.0 
Smoking      
Non-Smoker  1,143,297 82.7 462,827 87.5 
Smoker  232,823 16.8 63,260 12.0 
Missing  7,182 0.5 2,880 0.5 
Maternal Age at Infant Delivery  
(in years) 
     
Mean (Standard Deviation)  27.7 (5.6) 25.5 (5.6) 
Range  18.0-50.0 18.0-50.0 
Age at Breast Cancer Diagnosis  
(in years) 
     
Mean (Standard Deviation)  31.7 (4.6) 31.9 (4.9) 
Range  20.3-44.3 18.7-42.7 
Chemotherapya      
Didn’t receive chemotherapy  165 50.9 94 50.0 
Received chemotherapy  159 49.1 94 50.0 
Missing  0 0.0 0 0.0 
Length of Time between Diagnosis & 
Infant Deliverya 
     
 < 2 years  125 38.6 70 37.2 
2 ≤ years < 5  124 38.3 73 38.8 
≥ 5 years  75 23.1 45 23.9 
Missing  0 0.0 0 0.0 
N=total number; %=percentage 
a Includes only women with a breast cancer history (n=512) 
 
 
 
  
